Top

Theresa A. Guise, M.D., FASBMR

Department of Endocrine Neoplasia and Hormonal Disorders, Division of Internal Medicine

About Dr. Theresa A. Guise

OMB No. 0925-0001 and 0925-0002 (Rev. 03/2020 Approved Through 02/28/2023)

BIOGRAPHICAL SKETCH

NAME: Theresa A. Guise

eRA COMMONS USER NAME (credential, e.g., agency login): TAG4NNIH

POSITION TITLE: Professor and Chief, Section of Bone and Mineral Disorders

EDUCATION/TRAINING (Begin with baccalaureate or other initial professional education, such as nursing, include postdoctoral training and residency training if applicable. Add/delete rows as necessary.)

INSTITUTION AND LOCATION

DEGREE

Completion Date

FIELD OF STUDY

Gannon PA, Erie, PA

University of Pittsburgh, School of Medicine University of Pittsburgh, Heath Center

University of Texas, Health Sciences Center

B.S.

M.D.
Internship-
Residency
Fellow

05/1981

05/1985
06/1986
06/1988
06/1992

Biology
Medicine
Internal Medicine

Endocrinology

Personal Statement: My qualifications to serve as an Other Significant Contributor to Dr. Sue-Hwa Lin’s Project 2 of this Prostate Cancer SPORE proposal include 1) physician scientist endocrinologist with over 28 years research & training experience in animal models and human disorders of musculoskeletal complications of cancer and cancer treatment and most recently, on metabolism; 2) career focus on bone metastases, musculoskeletal health in the cancer patient as well as normal bone remodeling; 3) consistent funding and publications in complications of breast and prostate cancer and its treatment; 3) laboratory research group using basic molecular techniques, in vivo animal models and human studies in osteolytic and osteoblastic bone metastases due to breast, prostate, lung cancer, myeloma and melanoma; 4) active research program in cell biology of osteoclasts and osteoblasts; 5) establishment of muscle physiology laboratory to study the role of the bone microenvironment on cancer associated muscle weakness (ref: Contribution to Science #3a); 6) new research program to link increased bone destruction to diabetes mellitus; 7) founder and leader of the Tumor Microenvironment Program at Indiana University Simon Cancer Center (IUSCC); 8) training/mentoring of 33 postdoctoral fellows (24 Ph.D. and 9 Resident/Clinical), 3 Ph.D. students, 8 junior faculty and 28 summer (high school (8), undergrad (2) and medical students (18)) over 25 years; 9) providing reagents and training to study bone metastases to investigators world-wide; 10) described components of a feed-forward cycle between tumor and bone which fuels tumor growth and promotes muscle weakness; 11) active clinical practice of musculoskeletal complications in cancer patients at IUSCC; 12) leadership roles in ASCI, ASBMR, IBMS as well as permanent NIH study section member and Chair of SBSR, and Chairperson-elect for the Tumor Microenvironment Steering Committee (AACR). 13) continuous NIH funding since 1992, NCI since 1996.
Positions and Honors

1988-1989                    Clinical Instructor, Dept Medicine, University of Pittsburgh School of Medicine

1992-1998                    Assistant Professor, University of Texas Health Science Center/San Antonio, Dept Medicine, Div Endocrinology & Metabolism, San Antonio, TX

1998-2002                    Associate Professor w/Tenure, University of Texas Health Science Center/San Antonio, Dept Medicine, Div Endocrinology & Metabolism, San Antonio, TX

2001-2002                    Zachry Chair for Translational Research, Cancer Therapy & Research Center’s Institute for Drug Development, San Antonio Cancer Institute, San Antonio, TX

2001-2002                    Associate Professor (with tenure), University of Texas Health Science Center/San Antonio, Dept Molecular Medicine, San Antonio, TX

2002-2009       Gerald D. Aurbach Professor of Endocrinology, Professor, Medicine (tenure) & Orthopaedics, Div Endocrinology, Mellon Investigator, Univ. of Virginia, Charlottesville, VA

2009-2020      Jerry and Peg Throgmartin Professor of Oncology, Professor of Medicine (with tenure), Div Endocrinology, Professor of Pharmacology, Indiana University, Indianapolis, IN

Sept. 2020       Professor and Chief, Section of Bone and Mineral Disorders, Endocrine, Neoplasia and Hormonal Disorders; CPRIT Scholar, Univ of Texas MD Anderson Cancer Center, Houston, TX

Sept. 2020       Co-Director, Rolanette and Berdon Lawrence Bone Disease Program of Texas

Honors/Awards: National Research Service Award, NIH (1991); Clinical Investigator Award, NIH (1992); New Investigator Award, US Army (1992); FIRST Award, NIH (1996); Outstanding Investigator Award, International Bone & Calcium Institute (1998); Fuller Albright Award, American Society Bone & Mineral Research (1999); Young Investigator Award, Advances in Mineral Metabolism (2000); Zachry Chair for Translational Research, Institute for Drug Development, University of Texas (2001); Gerald D. Aurbach Professor Endocrinology, Endowed Chair & Mellon Investigator, University of Virginia (2002); American Society Clinical Investigation (2004; elected secretary/treasurer 2006); Association of American Physicians (elected 2008); Outstanding Mentor, University of Virginia (2008); Donald Coffey Lecture, Society for Basic Urologic Research (2009); Legacy Laureate, University of Pittsburgh (2009); Scientific Advisory Council, Komen Scholar, Susan G. Komen (2010-Present); Paula Stern Achievement Award, American Society for Bone and Mineral Research (2012); Philip S. Hench Distinguished Alumnus Award, University of Pittsburgh School of Medicine, Medical Alumni Association (2017); Presidential Address, Musculoskeletal Tumor Society of AAOS (2019); Avioli Memorial Lecture, ASBMR (2020); Cancer Prevention Research Institute of Texas (CPRIT) Scholar (2020); Stephen M. Krane Award, ASBMR (2020); Fellow, ASBMR (2020)

Professional Societies and Public Advisory Committees: Vice President, Cancer and Bone Society (2009); Board of Directors, Cancer and Bone Society (2008-Present); Program Leader of Tumor Biology and Microenvironment of the Indiana University Simon Cancer Center (2009-Presesnt); Member, Scientific Advisory Board, Institute of Molecular Medicine, Lisbon, Portugal (2007-2009); Skeletal Biology Structure & Regeneration Study Section, NIH (Chair: 2007-2009; Member: 2004-2007); Council Member and Secretary Treasurer, American Society for Clinical Investigation (2006-2010); Co-Chairman, 5th North American Skeletal Complications of Malignancy Meeting (2006); Member, Board of Directors, International Bone and Mineral Society (2005-2013); Co-Chairman, 6th North American Skeletal Complications of Malignancy Meeting (2005); Council Member, American Society for Bone and Mineral Research (2004-2007); Chairman, Education Committee, American Society for Bone and Mineral Research (2002-2005); Member, Board of Directors, Advances in Mineral Metabolism (2001-2004); Co-Chairman, Program Committee for the 2002 Annual Meeting of the American Society for Bone and Mineral Research (2001-2002); Member, Paget Foundation Board of Directors (2000-2014); Chairman of the Board, Paget Foundation (2010-2014); Vice President, International Bone and Mineral Society (2011-2013), President, International Bone and Mineral Society (2013-2015); Tumor Microenvironment (TME) Steering Committee, AACR (2017-2022); Program Committee, AACR Annual Meeting, 2019; Tumor Microenvironment Steering Committee, Chairperson of the TME working group, AACR (2019-2022); Council member, Association of Osteobiology (2019-2022); President, Association of Osteobiology (2022-)

C: Contribution to Science (Guise publications http://www.ncbi.nlm.nih.gov/pubmed/?term=guise+t)

>160 publications; career citations >25,000; h-index 70

1.Tumor-produced-produced factors in the bone microenvironment promote osteolytic bone destruction: Bone metastases cause pain and increase fracture risk. It was proposed for many years that tumor cells mediate bone destruction via osteoclasts: 1) tumors produce factors which stimulate osteoclast formation and activity; 2) histologic sections of bone metastases show tumor cells adjacent to bone-resorbing osteoclasts; 3) bisphosphonate inhibitors of bone resorption reduce bone destruction in bone metastases. However, the exact mechanisms were unknown when I entered the field in 1989. I established a cancer cell line from a lung cancer bone metastases from the first patient I saw as an endocrinology fellow, discovered that it produced parathyroid hormone-related protein (PTHrP) and developed a mouse model of PTHrP-dependent hypercalcemia and bone metastases (Ref a). These initial studies led to the discovery of: 1) the central role for tumor–secreted PTHrP (Ref b), and its downstream mediator, receptor activator of NF kappa B ligand (RANKL) (Ref c), in osteolytic breast cancer bone metastases. The studies lead to clinical trials using humanized anti-PTHrP antibodies in patients with breast cancer bone metastases (Ref b) and were the first to show that tumor-produced factors stimulate osteoclastic bone resorption via induction of host osteoblast RANKL (Ref c). Anti-RANKL is now FDA-approved therapy for bone metastases, is widely used, and the most effective bone-targeted therapy for this disease. In collaboration with Yibin Kang and Joan Massagué, we investigated the molecular basis of osteolytic tumor metastasis to bone by selecting populations of cells from the human MDA-MB-231 breast cancer with high bone metastatic activity and profiling gene expression (Ref d). The bone metastasis phenotype was specifically linked to high expression of a set of genes encoding secreted and cell surface proteins not shared by sister populations highly metastatic to adrenal gland. Two of the bone metastasis genes, CTGF and IL-11, encode angiogenic and osteoclastogenic factors, while others encode factors responsible for homing of cancer to bone (CXCR4) and invasion (MMP1). All are regulated by TGF-β and act cooperatively to promote osteolysis. Thus, cancer metastasis to bone requires the expression of a specific gene sets, the proteins of which act at different stages in the metastatic cascade as well as on specific functions in bone. It is unlikely that any one tumor-produced factor could drive the formation of osteolytic bone metastases, but rather a central factor, which regulates many of these tumor-produced prometastatic genes. TGF-β is a central regulator of these genes, and links to the second significant scientific contribution. NIH grants: R01-CA69158 (years 1-5 on PTHrP; years 6-16 on TGFb)

Guise TA, Yoneda T, Yates AJP, Mundy GR. The combined effect of tumor-produced parathyroid hormone-related peptide (PTHrP) and TGFa enhance hypercalcemia in vivo and bone resorption in vitro. J Clin Endocrinol Metab 77(1):40-45, 1993. PMID: 8325957.
Guise TA, Yin JJ, Taylor SD, Dallas M, Boyce BF, Yoneda T, Kumaga Y, Mundy GR. Evidence for a causal role of PTHrP in breast cancer mediated-osteolysis. J Clin Invest 98(7):1544-49, 1996.
Thomas, RJ, Guise, TA, Yin, JJ, Elliott, J, Horwood, NJ, Martin, TJ, Gillespie, M. Breast cancer cells interact with osteoblasts to support osteoclast formation. Endocrinol. 140(10):4451-8.1999
Kang, Y, Siegel, PM, Shu, WP, Drobnjak, M, Käkönen, SM, Cordon-Cardo, C, Guise, TA, Massagué, J A multigenic program mediating breast cancer metastases to bone. Cancer Cell 3(6):537-549. 2003

2.TGFb in the bone microenvironment promotes osteolytic bone metastases: Our studies on tumor-produced PTHrP as a mediator of bone destruction in breast cancer osteolysis led us to test the hypotheses that TGFb promotes osteolytic bone metastases by induction of tumor osteolytic factors, an idea that challenged existing dogma, since TGFb was known as a tumor suppressor. We showed that when MDA-MB-231 breast cancer was unresponsive to TGFb, tumor PTHrP production and bone metastases were blocked in vivo while enhanced TGFb signaling in MDA-MB-231 increased tumor PTHrP production and bone metastases (Ref a). These studies lead to development of TGFb inhibitors to treat bone metastases. Hypoxia is also a central regulator of pro-metastatic gene expression, so we asked whether hypoxia (via HIF-1α) and TGF-β signaling promote bone metastases independently or synergistically. Only vascular endothelial growth factor and the CXC chemokine receptor 4, of 16 genes tested, were additively increased by both TGFβ and hypoxia. We inhibited HIF-1α and TGF-β pathways in MDA-MB-231 breast cancer by shRNA and dominant negative receptor approaches. Inhibition of either pathway decreased bone metastasis, with no further effect of double blockade. In contrast, pharmacologic inhibitors of the pathways, which target both the tumor and the bone microenvironment decreased bone metastases more than either alone, with effects on bone to decrease osteoclastic bone resorption and increase osteoblast activity, in addition to effects on tumor cells. Thus, hypoxia and TGF-β signaling in parallel drive tumor bone metastases and regulate a common set of tumor genes. In contrast, small molecule inhibitors, by acting on both tumor cells and the bone microenvironment, additively decrease tumor burden and improve bone. These studies suggest that inhibitors of HIF-1alpha and TGF-b may reduce bone metastases and increase survival (Ref b). NIH grants: R01-CA69158. Most recent data are consistent with a role for bone-derived TGF-β, increased in states of high bone destruction, such as that induced by complete estrogen deprivation, to promote tumor growth in bone and muscle weakness (Ref c).

Yin, JJ, Selander, KS, Chirgwin, JM, Dallas, M, Grubbs, BG, Wieser, R, Massagué, J, Mundy, GR, Guise TA TGF-b signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. J Clin Invest. 103(2):197. 1999
Dunn LK, Mohammad KS, Fournier PGJ, McKenna CR, Davis HW, Niewolna M, Peng XP, Chirgwin JM, Guise TA. Hypoxia and TGF-β Drive Breast Cancer Bone Metastases through Parallel Signaling Pathways in Tumor Cells and the Bone Microenvironment. PLoS One. 2009 Sep 3;4(9):e6896. PMID: 19727403; PMCID: PMC2731927.
Wright LE, Harhash AA, Kozlow WM, Waning DL, Regan JN, She Y, John SK, Murthy S, Niewolna M, Marks AR, Mohammad KS, Guise TA. Aromatase inhibitor-induced bone loss increases the progression of estrogen receptor-negative breast cancer in bone and exacerbates muscle weakness in vivo. Oncotarget. 2016 Dec 25. doi:10.18632/oncotarget.14139. PMID: 28039445, PMCID: PMC5352410.

3.Pathologic states associated with oxidation of RyR: bone metastases-associated muscle dysfunction (via TGFb) and impaired glucose metabolism: Cancer-associated muscle weakness is poorly understood and there is no effective treatment. Six mouse models of human osteolytic bone metastases [breast, lung, prostate] and multiple myeloma, exhibited impaired muscle function, implicating a role for the tumor-bone microenvironment. TGF-β, released from bone, upregulated NADPH oxidase 4 (Nox4) oxidizing skeletal muscle proteins, including the ryanodine receptor/calcium (Ca²⁺)release channel (RyR1). Oxidized RyR1 channels leaked Ca²⁺reducing thesignal required for muscle contraction. Inhibiting RyR1 leak, TGF-β signaling, TGF-β release from bone or Nox4 all improved muscle function. Humans with breast or lung cancer bone metastases also had oxidized skeletal muscle RyR1. Similarly, skeletal muscle weakness, increased Nox4 and oxidation of RyR1 were present in a mouse model of Camurati-Engelmann disease, a non-malignant bone disorder associated with increased TGF-b. Thus, TGF-b released from bone contributes to muscle weakness by decreasing Ca²⁺-induced muscle force production. (Ref a) These are the first data showing that bone can regulate muscle function in a systemic manner in the setting of increased bone destruction due to cancer or other high bone turnover states. R01-CA69158, U01-CA143057. In collaboration with Marks laboratory, oxidation of RyR2 impairs insulin secretion and glucose metabolism. (Ref. b).

Waning DL, Mohammad KS, Reiken S, Xie W, Andersson DC, John S, Chiechi A, Wright LE, Umanskaya A, Niewolna M, Trivedi T, Charkhzarrin S, Khatiwada P, Wronska A, Haynes A, Benassi MS, Witzmann FA, ZhenG, WangX, Cao X, RoodmanGD, Marks AR, Guise TA Excess TGFβ mediates muscle weakness associated with bone metastases in mice. Nature Medicine, 2015 Oct 12. doi: 10.1038/nm.3961. PMID: 26457758, PMCID: PMC4636436. featured on cover; News and Views
Santulli G, Pagano G, Sardu C, Xie W, Reiken S, Luca D’Ascia S, Cannone M, Marziliano N, Trimarco B, Guise TA, Lacampagne A, Marks AR Ryanodine receptor/calcium release channel regulates insulin release and glucose homeostasis. J Clin Invest, 2015 Apr 6. pii: 79273. doi: 10.1172/JCI79273. PMID:25844899, PMCID: PMC4463204

4.The TGFβ signaling regulator PMEPA1 suppresses prostate cancer metastases to bone: TGFβ regulates the expression of genes promoting breast cancer osteolysis, but little is known about TGFβ regulation of prostate cancer bone metastases. We showed that 1) TGFbR1 blockade reduced prostate cancer bone metastases; 2) TGFβ upregulates a set of genes associated with cancer invasiveness and bone metastases: the most upregulated gene was PMEPA1. In patients, PMEPA1 expression decreased in metastatic prostate cancer and low Pmepa1 correlated with decreased metastasis-free survival. Only membrane-anchored isoforms of PMEPA1 interacted with R-SMADs and ubiquitin ligases, blocking TGFβ signaling independently of the proteasome. Interrupting this negative feedback loop by PMEPA1 knockdown increased prometastatic gene expression and prostate cancer bone metastases in mice. Thus, in prostate cancer, TGFβ controls the expression of a pro-metastatic gene program similar to breast cancer, supporting the use of TGFβ inhibitors to treat prostate cancer bone metastases . PMEPA1 knock-down increased bone metastases. The identification of PMEPA1 as a major target of TGFβ and negative feedback regulator of TGFβ signaling suggests that PMEPA1 might be a useful prognostic marker of metastases to TGFβ-rich sites and predictor of metastasis-free survival. Enhancing membrane-bound PMEPA1 activity could be used as treatment strategy against prostate cancer bone metastases. (Ref a) R01-CA69158, U01-CA143057

Fournier PG, Juárez P, Jiang G, Clines GA, Niewolna M, Kim HS, Walton HW, Peng XH, Liu Y, Mohammad KS, Wells CD, Chirgwin JM, Guise TA. The TGF-β Signaling Regulator PMEPA1 Suppresses Prostate Cancer Metastases to Bone. Cancer Cell. 2015 May 12. pii: S1535-6108(15)00142-7. doi: 10.1016/j.ccell.2015.04.009. PMID: 25982816, PMCID: PMC4464909.

5.Endothelins and the Wnt pathway in the pathophysiology of osteblastic bone metastases: Certain cancers, such as prostate and breast, stimulate abnormal bone formation as well as bone destruction, but there were no models in the 1990’s to define pathophysiology. These osteoblastic bone metastases are associated with similar morbidity as osteolytic bone metastases. We discovered the first mouse model of osteoblastic bone metastases (Ref a). Tumor-produced endothelin-1 (ET-1) caused the abnormal bone formation and the progression of bone metastases in a mouse model of osteoblastic bone metastases due to breast cancer (Ref a) by acting on the endothelin A receptor of the osteoblast (ETAR); later studies revealed that tumor-produced ET-1 mediated its effects by suppression of osteoblast DKK1 to activate the Wnt signaling pathway (Ref b). The ETAR antagonist (atrasentan, Abbott) had no effect on tumor burden when the breast cancers were at sites outside of bone, such as in the primary site. These results confirmed the bone-specific nature of ETAR blockade and suggested that cancer treatment with ETAR antagonists would be beneficial for patients with bone metastases, but not for extraskeletal tumors. However the phase III study used overall survival as the primary endpoint and it was terminated early because interim analysis revealed that the primary endpoint (overall survival) would not be achieved. A subset analysis of the prostate cancer patients with bone metastases revealed that these patients had improved survival and delayed progression of bone metastases. Astrazeneca designed the appropriate phase III trial to treat men with prostate cancer patients with bone metastases with zibotentan in addition to the prostate cancer treatment. Zwibotetan reduced the progression of bone metastases (James et al., 2010 BJU Int. 106:966-73). However, as with atrasentan, a separate phase III trial of zibotentan as a general anticancer single agent failed. Collectively, these examples of dissecting the mechanisms for bone metastases as the basis for bone-targeted therapy of this devastating complication of cancer illustrate the innovativeness to challenge existing paradigms in cancer therapy. The studies on the role of ET-1 in the pathophysiology of osteoblastic bone metastases led to investigating the role for ET-1 in normal bone remodeling. We generated a mouse with targeted deletion of ETAR in the osteoblast and showed that ET-1 was important for the maintenance of normal bone mass in the setting of androgen deficiency (Ref c). Thus, men with prostate cancer, treated with androgen deprivation and ETAR are at risk for bone loss. NIH grants: P01CA40035, R01DK067333

Yin JJ, Mohammad KS, Käkönen SM, Harris S, Wu-Wong JR, Wessale J, Padley R, Garrett IR, Chirgwin JM, Guise,TA A causal role for endothelin-1 (ET-1) in the pathogenesis of osteoblastic bone metastases. Proc Natl Acad Sci USA. 2003 100(19):10954-9. PMID: 12941866 PMCID: PMC196909.
Clines GA, Mohammad KS, Bao Y, Stephens OW, Suva LJ, Shaughnessy JD Jr, Fox JW, Chirgwin JM, Guise TA. Dickkopf homolog 1 (Dkk1) mediates endothelin-1-stimulated new bone formation. Mol Endocrinol. 21(2):486-98, Feb 2007. Epub 2006 Oct 26. PMID: 17068196, PMCID: PMC2013302
Clines GA, Mohammad KS, Grunda JM, Clines KL, Niewolna M, McKenna CR, McKibbin CR, Yanagisawa M, Suva LJ, Chirgwin JM, Guise TA. Regulation of postnatal trabecular bone formation by the osteoblast endothelin A receptor. J Bone Miner Res. 2011 Oct;26(10):2523-36. doi: 10.1002/jbmr.450. PMID: 21698666, PMCID: PMC3183222.

D: Additional Information: Research Support and/or Scholastic Performance

Ongoing Research Support

R01CA206025 (Guise, contact PI; Territo, PI; Marks, PI) 05/01/2016-04/30/2021

NIH/NCI

Title: (PQ#9) Targeting leaky ryanodine receptor (RyR2) to treat and prevent chemotherapy-associated cognitive dysfunction in patients with breast cancer

Goal: Determine if oxidation of RyR2 is associated with chemotherapy-induced cognitive dysfunction and whether rycal stabilization of RyR2 can prevent cognitive dysfunction.

BC171929 (Guise, PI) 9/01/2018 – 02/14/2022

Department of Defense Breast Cancer Research Program

Title: Role of Bone-derived TGF-beta on Glucose Metabolism in the Setting of Breast Cancer Bone Metastases

Goal: To determine if systemic effects of TGF-b derived from bone destruction induce hyperglycemia by oxidation of pancreatic RyR2 and suppressed insulin secretion.

RR190108 (Guise, PI) 06/01/2020-05/31/2025

Cancer Research Prevention Institute of Texas (CPRIT)

Title: Established Investigator Award

Metabolic complications of cancer and cancer treatment-induced bone destruction: Role of TGFβ-mediated oxidation.

Completed Research Support: (past 3 years)

P30CA082709-14 (Loehrer, PI; Guise, Co-Leader Tumor Microenvironment Program)

NIH/NCI Cancer Center Support Grant 09/01/2019-08/31/2024

Overall: Facilitate cancer research, education, care, and cancer control and prevention to accomplish the mission of reducing the incidence, morbidity, and mortality of cancer.

DOD BC150678 (Guise, PI; Thompson, Partner PI) 01/01/2016-01/31/2020

Title: Effect of Low-Magnitude Mechanical Signals on Breast Cancer Bone Metastases

Study low magnitude mechanical signals, alone or in combination with bisphosphonates, on bone and muscle loss resulting from aromatase inhibitors as well as breast cancer bone metastases

1 I01 BX002764-01A1 (Nakshatri; PI, Guise; Co-I) 04/01/2015-03/31/2019

VA Merit Award Title: Mechanisms associated with systemic effects of cancer.

Study mechanisms of cancer cachexia and therapeutic modalities of miR-486, DMAPT and lospamimod.

BC134025 (Wright, PI; Guise, Mentor) 07/15/2014 – 07/14/2018

DOD, Breast Cancer Research Program

Title: Musculoskeletal complications and bone metastases in breast cancer patients undergoing estrogen deprivation therapy.

The objective of this postdoctoral training grant is to evaluate the effects of aromatase inhibitor therapy on the musculoskeletal system in the context of breast cancer bone metastases.

U01 CA143057 (Guise; PI) 04/07/2011 – 03/31/2017

NIH/NCI

Title: Differential TGF-Beta Signaling in Bone Microenvironment: Impact on Tumor Growth.

The goal is to compare bone cell-specific alterations in TGF-b signaling (host) with systemic inhibition of TGF-b (host & tumor) to target TGF-b to treat bone metastases.

What causes chemobrain? New insights

Present Title & Affiliation

Dual/Joint/Adjunct Appointment

Professor, Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, TX

Education & Training

Degree-Granting Education

1985	University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, US, MD

Postgraduate Training

1989-1992	Clinical Fellowship, Endocrinology and Metabolism, University of Texas Health Science Center, San Antonio, Texas
1986-1992	Clinical Residency, Internal Medicine, University of Pittsburgh Health Center, Pittsburgh, Pennsylvania
1985-1986	Clinical Internship, Internal Medicine, University of Pittsburgh Health Center, Pittsburgh, Pennsylvania

Licenses & Certifications

2023	Drug Enforcement Agency
1989	Texas Medical Board License
1988	American Board of Internal Medicine
1986	National Board of Medical Examiners

Experience & Service

Faculty Academic Appointments

Professor of Pharmacology, Indiana University, Indianapolis, Indiana, 2010 - 2020

Professor with tenure, Department of Medicine, Indiana University, Indianapolis, IN, 2009 - 2020

Professor with tenure, Department of Medicine, University of Virginia, Charlottesville, VA, 2002 - 2009

Associate Professor with tenure, The University of Texas Health Science Center at San Antonio, San Antonio, TX, 2001 - 2002

Associate Professor with tenure, Department of Medicine, The University of Texas Health Science Center at San Antonio, San Antonio, TX, 1999 - 2002

Associate Professor, The University of Texas Health Science Center at San Antonio, San Antonio, TX, 1998

Assistant Professor, Department of Medicine, The University of Texas Health Science Center at San Antonio, San Antonio, TX, 1992 - 1998

Clinical Instructor, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, 1988 - 1989

Administrative Appointments/Responsibilities

Section Chief, Bone and Mineral Disorders, Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, TX, 2020 - Present

Other Professional Positions

Member, Molecular and Translational Biology and Therapeutics and Pharmacology, The University of Texas MD Anderson Cancer Center at Houston, Houston, Texas, 2024 - Present

Abell-Hanger Foundation, The University of Texas MD Anderson Cancer Center, Houston, TX, 2022 - Present

Scholar, Cancer Prevention Research Institute of Texas, Houston, TX, 2021 - Present

Co-Director, Rolanette and Berdon Lawrence Bone Disease Program of Texas, The University of Texas MD Anderson Cancer Center, Houston, TX, 2020 - Present

Jerry and Peg Throgmartin Professor of Oncology, Indiana University, Indianapolis, IN, 2009 - 2020

Gerald D. Aurbach Professor of Endocrinology, University of Virginia, Charlottesville, VA, 2002 - 2009

Extramural Institutional Committee Activities

Member, Endowed Positions and Awards Committee, The University of Texas MD Anderson Cancer Center, 2022 - Present

Member, Experimental Therapeutics/Systems Biology Joint Department Chair Search, The University of Texas MD Anderson Cancer Center, 2021 - Present

Member, Multidisciplinary Research Advisory Committee, The University of Texas MD Anderson Cancer Center, 2021 - Present

Mentor, CPRIT TRIUMPH Postdoctoral Fellowship Training Grant, The University of Texas MD Anderson Cancer Center, 2021 - Present

Member, Search Committee to select Cancer Center Director, Indiana University Simon Cancer Center, The University of Texas MD Anderson Cancer Center, 2019

Member, Indiana University, Review Panel Grand Challenges Grants, The University of Texas MD Anderson Cancer Center, 2015 - 2016

Member, Committee to select the Founding Dean, Richard M. Fairbanks School of Public Health, IUPUI, The University of Texas MD Anderson Cancer Center, 2012

Member, Physician Scientist Advisory Committee, Indiana University School of Medicine, The University of Texas MD Anderson Cancer Center, 2010 - 2013

Member, Strategic Planning Research Committee, Indiana University School of Medicine, The University of Texas MD Anderson Cancer Center, 2010 - 2012

Member, Research Advisory Committee, University of Virginia School of Medicine, The University of Texas MD Anderson Cancer Center, 2007 - 2009

Member, Committee to review reappointment of Dean, University of Virginia, The University of Texas MD Anderson Cancer Center, 2006

Member, Search Committee, Associate Dean for Clinical Research, University of Virginia, The University of Texas MD Anderson Cancer Center, 2004

Member, Howard Hughes Medical Institute Executive Committee, UTHSCSA, The University of Texas MD Anderson Cancer Center, 2002

Member, Internal Medicine Residency Selection Committee, UTHSCA, The University of Texas MD Anderson Cancer Center, 1998 - 2001

Member, Competitive Research Enhancement Fund Review Committee, UTHSCSA, The University of Texas MD Anderson Cancer Center, 1998 - 2002

Member, General Clinical Research Center Advisory Committee, UTHSCSA, The University of Texas MD Anderson Cancer Center, 1996 - 2001

Member, Institutional Animal Care and Use Committee, UTHSCSA, The University of Texas MD Anderson Cancer Center, 1996 - 2000

Member, Cancer Coordinating Committee, UTHSCSA, The University of Texas MD Anderson Cancer Center, 1995 - 1997

Member, Medical School Strategic Planning Committee, UTHSCSA, The University of Texas MD Anderson Cancer Center, 1995

Editorial Activities

Editor, Journal of Bone Oncology, 2015 - Present

Associate Editor, Primer on the Metabolic Bone Diseases and Disorders of Mineral, 7th Edition, 2009 - Present

Associate Editor, NCI Special Emphasis Panel for Breast Cancer Insight Awards, 2007 - 2012

Associate Editor, Journal of Bone and mineral Research, 2007 - 2012

Editor, Bone, 2006 - 2009

Editor/Service on Editorial Board(s), Bone, 2006 - 2009

Editor, Endocrinology, 2004

Editor/Service on Editorial Board(s), Endocrinology, 2004

Editor, Journal of Bone and Mineral Research, 2003 - 2008

Editor/Service on Editorial Board(s), Journal of Bone and Mineral Research, 2003 - 2008

Editor, Journal of Clinical Endocrinology and Metabolism, 2001 - 2004

Editor, Clinical and Translational Science, 2001

Editor/Service on Editorial Board(s), Journal of Clinical Endocrinology and Metabolism, 2001 - 2004

Professional Memberships

European Association for Cancer Research (EACR)-American Association for Cancer Research (AACR) Basic and Translational Research Conference 2020 with ASPIC: Tumor Microenvironment

2020

Van Andel Research Institute (VARI) External Scientific Advisory Board

2014 - Present

American Society of Clinical Oncology

2013 - Present

Novartis International AG

2013

Susan G. Komen Foundation

2010 - 2016

Association of American Physicians

2008 - Present

Institute of Molecular Medicine

2008 - 2011

Bone and Cancer Foundation

2008 - Present

Cancer and Bone Society

2008 - Present

American Association for Cancer Research

2005 - Present

Ninth International Endothelin Meeting

2005

American Society for Clinical Investigation

2004 - Present

NIH, Skeletal Biology Structure & Regeneration Study Section

2004 - 2009

Advances in Mineral Metabolism

2001 - 2004

Paget Foundation

2000 - Present

Association of Osteobiology

1999 - Present

International Bone and Mineral Society

1998 - Present

Women in Endocrinology

1994 - Present

American Association for the Advancement of Science

1993 - Present

Endocrine Society

1993 - Present

American Society for Bone and Mineral Research

1991 - Present

Selected Presentations & Talks

Local Presentations

2025. 380.Role of pathologic bone resorption on cognitive function: Implications for cancer and treatment. Invited. Cancer Neuroscience Scientific Retreat. Houston, Texas, US.
2016. Cancer-associated muscle weakness: what’s bone got to do with it?. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.

Regional Presentations

2022. Systemic effects of pathologic bone remodeling. Houston, Texas, US.
2006. Skeletal complications of cancer and cancer treatment. Conference. Bone Club. San Antonio, TX, US.
1997. Parathyroid hormone-related protein (PTHrP)-(1-139) isoform is efficiently secreted in vitro and enhances breast cancer metastasis to bone in vivo. Conference. Texas Mineralized Tissue Society. Corpus Christi, TX, US.
1996. Treatment of osteoporosis: 1996 and Beyond. Conference. Texas Medical Association. San Antonio, TX, US.

National Presentations

2024. Anabolic agents and patients with cancer. Is there a role in bone health?. Invited, US.
2024. Bad to the Bone: Systemic Effects of Pathologic Bone Resorption. Invited. Pathology Grand Rounds. Denver, Colorado, US.
2024. Use of anabolic agents to treat osteoporosis. Invited, New Mexico, US.
2023. Systemic effects of bone destruction on muscle function. Invited. Chicago, Illinois, US.
2023. Why Do Hormone-Dependent Cancers Love Bone?. Invited. Enodcrine Society Annual Meeting ENDO 2023. Chicago, IL, US.
2023. Bad to the bone: effects of pathologic bone destruction on muscle. Special Symposium. Invited. American Association for Cancer Research Annual Meeting. Orlando, FL, US.
2023. Systemic effects of bone destruction on muscle function. Invited. Orlando, Florida, US.
2022. Breast cancer bone metastases and diabetes. Invited, California, US.
2022. Challenging bone cases. Invited. Austin, US.
2022. Bad to the bone: Systemic effects of pathological bone destruction. Invited. New Orleans, Louisiana, US.
2022. Bad to the bone: Systemic effects of pathological bone destruction. Major Symposium: Bone Metastases. Invited. American Association for Cancer Research Annual Meeting. New Orleans, LA, US.
2021. Systemic consequences of pathologic bone remodeling in cancer and cancer treatment. Haddad Memorial Lecture, US.
2020. Cancer, bone and beyond: an integrated view of the bone microenvironment and pathologic bone resorption. Invited. Gallick Laboratory Meeting, GU Oncology, MD Anderson Cancer Center. Houston, TX, US.
2020. Cancer, bone and beyond: an integrated view of the bone microenvironment and pathologic bone resorption. Invited. Research Seminar, Department of Orthopaedics, University of Pittsburgh. Pittsburgh, PA, US.
2020. Cancer, bone and beyond: an integrated view of the bone microenvironment. Invited. Systemic Effects of Metastatic Cancer Symposium at the New York Academy of Sciences. New York, NY, US.
2020. Cancer and bone: From the vicious cycle to an integrated view of the bone microenvironment. Invited. Louis Avioli Memorial Lecture. Seattle, WA, US.
2020. Cancer, bone and beyond: an integrated view of the bone microenvironment. Invited. The Origins of Cancer Meeting. Grand Rapids, MI, US.
2020. Management of Osseous Metastases: An Endocrinologist’s Perspective. Invited. American Society for Clinical Oncology. Chicago, IL, US.
2019. Cancer, bone, muscle and metabolism: what’s the connection?. Invited. Presidential Guest Speaker. Portland, OR, US.
2019. Cancer-associated bone destruction: is there an effect on metabolism?. Invited. Educational Symposium. Atlanta, GA, US.
2018. Role of bone-derived TGFß on glucose homeostasis: Implications for states increased bone destruction. Invited. Musculoskeletal Biology and Bioengineering. Andover, NH, US.
2018. Bone destruction: is there an effect on metabolism?. Invited. Novel Aspects of Bone Biology. Snowbird, UT, US.
2018. Cancer associated muscle dysfunction: what’s bone got to do with it?. Invited. Endocrine Society Meeting. Chicago, IL, US.
2018. Cancer, muscle and bone interactions in breast cancer. Invited. Laura Evans Memorial Breast Cancer Symposium. Sun Valley, ID, US.
2018. Bone destruction: is there an effect on metabolism?. Conference. Bones and Teeth, Gordon Research Conference. Galveston, TX, US.
2018. Bone destruction: is there an effect on metabolism?. Invited. Bones and Teeth, Gordon Research Conference. Galveston, TX, US.
2016. Bone-derived TGFβ mediates muscle weakness associated with osteolytic bone metastases. Invited. TGFβ Superfamily Meeting. Boston, MA, US.
2016. Mechanisms of muscle weakness associated with bone to muscle cross-talk. Special symposium on muscle and bone. Invited. Muscular Dystrophy Association. Washington, DC, US.
2015. Swimming with sharks: underwater integration of science and art. Invited. Association of Osteobiology. Seattle, WA, US.
2015. (1) Biology of bone metastases (2) Biology of multiple myeloma and MGUS-associated bone disease. Invited. Northern California Institute for Bone Health, 11th Annual meeting. Oakland, CA, US.
2015. Musculoskeletal effects of cancer and cancer treatment. Invited. Advances in Mineral Metabolism Meeting. Snowmass, CO, US.
2015. Cancer, bone and muscle: it’s all about the microenvironment. Invited. Endocrine Society. San Diego, CA, US.
2014. (1) Molecular mechanisms of muscle dysfunction in patients with bone metastases: role of the bone microenvironment in regulating muscle function (2) Alternate sources of funding: how to obtain! Career Development Symposium. Invited. American Society for Bone and Mineral Research. Houston, TX, US.
2014. TGF-ß signaling in bone metastases: Impact of the tumor microenvironment on muscle function. Invited. Tumor Microenvironment Network. New York, NY, US.
2014. New therapy to treat bone metastases. Invited. 23rd Annual Scientific and Clinical Congress Program. Las Vegas, NV, US.
2013. Cancer-associated muscle dysfunction: role of the bone microenvironment. Invited. American Association for Cancer Research. Washington, DC, US.
2011. Differential TGF-B signaling in the bone microenvironment: Impact on Tumor Growth. Invited. Tumor Microenvironment Network Meeting. Bethesda, MD, US.
2010. Molecular mechanisms of bone metastases: implications for therapy. Invited. Tumor Microenvironment Meeting. Bethesda, MD, US.
2010. Molecular mechanisms of bone metastases: implications for therapy. Invited. Endocrine Society. San Diego, CA, US.
2010. Targeting the bone microenvironment to treat bone metastases: new drugs and new insight into old drugs. Invited. Colloquium on Ageing/Frailty. Boston, MA, US.
2010. What makes bone a preferential site for metastases?. Invited. American Society for Cancer Research. Washington, DC, US.
2009. Events in the bone microenvironment: Mechanism of action of bisphosphonates. Conference. San Antonio Breast Cancer Meeting. San Antonio, TX, US.
2009. (1) TGF-ß: Cancer, Bone and Beyond (2) Role of RANKL/RANK/OPG in skeletal complications of malignancy. Invited. Korea National Osteoporosis Society Meeting. Seoul.
2009. Anti-tumor effects of bone-targeted agents in bone metastases. Invited. Third Cambridge Consensus Conference. Washington, DC, US.
2009. Clinical and translational elements of RANKL pathway in cancer and bone. Invited. State-of-the-Art Symposium. Denver, CO, US.
2009. Mechanisms underlying cancer metastasis. Conference. The New York Academy of Sciences. New York, NY, US.
2009. Transforming growth factor beta: Cancer, bone and beyond. Invited. Coffey Lecture for Society for Basic Urologic Research and Society of Urologic Oncology. Chicago, IL, US.
2008. Molecular mechanisms of solid tumor metastasis to bone. Invited. Research Symposium. Salt Lake City, UT, US.
2008. TGFβ: Cancer, bone and beyond. Invited. Endocrine Society Annual Meeting. San Francisco, CA, US.
2008. TGFβ: Role in site-specificity of metastases to bone. Invited. American Association for Cancer Research Annual Meeting. San Diego, CA, US.
2008. Transforming growth factor beta (TGF-beta): Role in bone metastases due to breast cancer, prostate cancer and melanoma. Invited. Keystone Symposia. Santa Fe, NM, US.
2007. TGFβ signaling in bone metastases due to breast cancer, prostate cancer and melanoma. Conference. Skeletal Complications of Malignancy Meeting. Philadelphia, PA, US.
2007. Cancer and bone. Invited. National Academy of Continuing Medical Education. Fort Lauderdale, FL, US.
2007. TGFβ-regulated genes in prostate cancer. Invited. IMPACT meeting. Atlanta, GA, US.
2007. TGFβ signaling in breast cancer bone metastases: Friend or foe?. Invited. Advances in Mineral Metabolism Annual Meeting. Snomass, CO, US.
2007. Biology of bone metastases. Invited. Federation of American Societies for Experimental Biology. Washington, DC, US.
2007. Skeletal health in the cancer patient. Conference. State of Maine. Sugarloaf, ME, US.
2006. TGFβ signaling in breast cancer bone metastases: Friend or foe?. Invited. Cancer and Bone Society. San Antonio, TX, US.
2006. (1) TGFβ in bone metastases (2) RANK ligand in pathological bone remodeling (3) Molecular mechanisms of bone metastases; Insight into pathophysiology. Invited. American Society for Bone and Mineral Research Annual Meeting. Philadelphia, PA, US.
2006. Bisphosphonate update 2006. Invited. 26th Annual Scripps Health Clinical Hematology and Oncology Meeting. San Diego, CA, US.
2005. What makes bone a favorable site for metastases?. Invited. Tumor Microenvironment and Protease Meeting. Bonita Springs, FL, US.
2005. Targeting the endothelin axis in osteoblastic bone metastases: Mechanisms and implications. Invited. Prostate Cancer Foundation. Scottsdale, AZ, US.
2005. Endothelin-1 in osteoblastic bone metastases: Mechanisms and therapeutic implications. Invited. Experimental Biology Annual Meeting. San Diego, CA, US.
2005. Mechanisms of osteoblastic bone metastases. Invited. Fourth North American Symposium Skeletal Complications of Malignancy. Bethesda, MD, US.
2005. Blockade of TGFß signaling in breast cancer metastases to bone. Invited. Keystone Symposia. Keystone, CO, US.
2005. Molecular mechanisms of osteoblastic bone metastases. Invited. Orthopedic Research Society Meeting. Washington, DC, US.
2004. Molecular mechanisms of bone metastases. Invited. Endocrinology Grand Rounds. Bethesda, MD, US.
2004. Molecular mechanisms of bone metastases. Invited. National Cancer Institute. Bethesda, MD, US.
2004. Endothelin A receptor blockade and bisphosphonate therapy in prostate cancer bone metastases. Invited. Prostate Cancer Foundation Scientific (formerly CAPCURE). Lake Tahoe, NV, US.
2004. (1) Tumor stimulation of the osteoblast (2) Cancer and Bone. Invited. Ninth Annual Meeting, Skeletal Metastasis: Tumor Interactions with the Bone Microenvironment. Seattle, WA, US.
2004. Mechanisms of bone destruction in breast and prostate cancer. Invited. Endocrine Society Meeting. New Orleans, LA, US.
2004. Mechanisms of bone metastases. Invited. Research Seminar, National Cancer Institute. Bethesda, MD, US.
2003. Current role of bisphosphonates in cancer management. Conference. Southern Association of Oncology. Charleston, SC, US.
2003. Tumor cell-bone cell interactions Implicated in bone metastasis. Conference. The Harvard Club of Boston. Boston, MA, US.
2003. Bone complications of malignancy. Invited. Make a Difference in Oncology Meeting. Phoenix, AZ, US.
2002. (1) Breast cancer metastases to bone: Role of TGFß (2) Molecular mechanisms of osteoblastic bone metastases. Invited. Bone Metastases Symposium of the Association of Bone and Joint Surgeons. Tampa, FL, US.
2002. Use of bisphosphonates for bone tumors. Invited. Children’s Oncology Group Meeting. St. Louis, MO, US.
2002. Mechanisms of prostate cancer metastases to bone: Preclinical data. Conference. Southwest Oncology Group. Houston, TX, US.
2002. The vicious cycle of bone metastases. Invited. Sun Valley Hard Tissue Workshop. Sun Valley, ID, US.
2002. Role of inflammatory cytokines in the disordered bone remodeling in cystic fibrosis. Invited. Consensus on bone disease in cystic fibrosis. Bethesda, MD, US.
2002. Role of endothelin-1 in osteoblastic bone metastases. Invited. Paget Foundation-NIH sponsored symposium. Bethesda, MD, US.
2001. Biology and treatment of bone metastasis. Invited. New Discoveries in Prostate Cancer Biology and Treatment. Naples, FL, US.
2001. TGFß in breast cancer metastases to bone. Conference. San Antonio Breast Cancer Symposium. San Antonio, TX, US.
2001. (1) Skeletal complications of malignancy (2) Skeletal metastases: Subversion of normal bone remodeling by cancer cells. Invited. American Society for Bone and Mineral Research Meeting. Phoenix, AZ, US.
2001. Influence of inflammatory cytokines on bone remodeling in cystic fibrosis. Invited. National Meeting for the Cystic Fibrosis Foundation. Orlando, FL, US.
2001. Metastatic mechanisms for tumors. Invited. Molecular Biology in Orthopaedics, American Association of Orthopaedic Surgeons Workshop. Scottsdale, AZ, US.
2001. Clinical insights into biology of the osteoblast. Invited. Symposium on novel anabolic approaches to osteoporosis. Denver, CO, US.
2001. Molecular mechanisms in metastases. Invited. Conference on Cellular and Molecular Aspects of Omega-3 Fatty Acids and Cancer. Breckenridge, CO, US.
2001. Molecular mechanisms of osteolytic metastases. Invited. Rocky Mountain Oncology Society. Denver, CO, US.
2001. Mechanisms of bone metastases: implications for therapy. Invited. Oncology Research Conference. Denver, CO, US.
2000. Cancer and Hypercalcemia. Invited. Ashland Endocrine Conference. Ashland, OR, US.
2000. PTHrP in bone metastases: Regulation by TGFß. Invited. Advances in Mineral Metabolism Annual Meeting. Snowmass, CO, US.
1999. Breast cancer metastases to bone: Role of PTHrP and TGFß. Invited. Breast Cancer Research Seminar. Nashville, TN, US.
1999. Role of TGFß in breast cancer metastases to bone. Invited. Signaling Molecules in Breast Cancer Symposium. San Diego, CA, US.
1999. Pathophysiology of breast cancer metastases to bone and myeloma. Invited. Oncology Nurse’s Society. Atlanta, GA, US.
1998. Bone metastases and parathyroid hormone-related protein secretion by breast cancer cells are regulated by transforming growth factor-beta. Invited. American Society for Biochemistry and Molecular Biology Symposia. Taos, NM, US.
1998. Role of PTHrP and TGFß in breast cancer metastases to bone. Invited. Biomechanics and Bio-engineering, Proctor Academy, NH, US.
1997. The role of parathyroid hormone-related protein in breast cancer metastasis to bone. Invited. US Army Medical Research and Materiel Command Breast Cancer Research Program: An Era of Hope. Washington, DC, US.
1997. PTHrP and Bone Metastases. Invited. Paget Foundation sponsored symposium. Bethesda, MD, US.
1996. Mechanisms of breast cancer metastasis to bone. Conference. Fifth Annual San Antonio Cancer Institute Symposium. San Antonio, TX, US.
Pathogenesis of humoral hypercalcemia. Invited. University of Colorado Health Sciences Center. Denver, CO, US.
Animal models of humoral hypercalcemia. Invited. University of Colorado Health Sciences Center. Denver, CO, US.

International Presentations

2025. Brain-bone connection Korean Society of Bone and Mineral Research Meeting. Visiting, KR.
2025. Effects of pathologic bone resorption on cognition. Invited, KR.
2025. Systemic effects of pathologic bone destruction on muscle function,. Invited, KR.
2025. Cancer-associated cachexia. Invited, AT.
2025. The bone and brain connection. Excellence in Research Award. Invited, AT.
2025. Bad to the Bone: Systemic effects of pathologic bone destruction. Invited, BB.
2024. Use of denosumab in breast cancer: Against the motion. Panelist, CA.
2024. Challenging cases. Invited, GB.
2023. Use of anabolic agents for bone health in cancer patients. Invited. Vancouver, CA.
2021. Cancer, bone and beyond: an integrated view of the bone microenvironment and pathologic bone resorption. Invited. Crick International Cancer Conference, the Francis Crick Institute. London, GB.
2020. Cancer, bone and beyond: an integrated view of the bone microenvironment and pathologic bone resorption. Invited. 13th international Sarcopenia Cachexia Muscle Wasting Disorders virtual digital conference. Houston, US.

Formal Peers

2023. Cancer, bone and beyond: an integrated view of the bone microenvironment. Invited. Heidelberg, DE.
2021. Systemic consequences of pathologic bone remodeling in cancer and cancer treatment. Invited, US.
2021. Bad to the bone: Systemic effects of pathological bone destruction. Invited. Houston, TX, US.
2020. Cancer, bone and beyond: an integrated view of the bone microenvironment. Invited. New York, NY, US.
2019. Bone-derived TGF-β Impairs Glucose Metabolism and Insulin Release by Oxidation of RyR2 Ca2+ Release Channel in Pancreatic β-cells in the Setting of High Bone Turnover, Aging and High Fat Diet. Invited. Indianapolis, IN, US.
2019. Cancer-associated bone destruction: is there an effect on metabolism?. Invited. Durham, NC, US.
2019. Cancer-associated bone destruction: is there an effect on metabolism?. Invited. Tuscon, AZ, US.
2019. Role of bone-derived TGFß on glucose homeostasis: Implications for states increased bone destruction. Invited. Portland, OR, US.
2019. Cancer, bone, muscle and metabolism: what’s the connection?. Invited. Houston, TX, US.
2019. Cancer, bone, muscle and metabolism: what’s the connection?. Invited. Sacramento, CA, US.
2018. Beyond Jaws: an Exposé on Shark s. Invited. Erie, PA, US.
2018. Cancer, bone, muscle and metabolism: what’s the connection?. Invited. Dallas, TX, US.
2018. Cancer-associated muscle dysfunction: what’s bone got to do with it?. Invited. Philadelphia, PA, US.
2017. Cancer-associated muscle weakness: what’s bone got to do with it?. Invited. Ensenada, MX.
2017. Cancer-associated muscle weakness: role of the bone microenvironment. Invited. London, Ontario, CA.
2017. Cancer-associated muscle weakness: what’s bone got to do with it?. Invited. Leiden, NL.
2017. (1) Cancer-associated muscle weakness: what’s bone got to do with it? (2) Effect of bone destruction on metabolism. Invited. San Francisco, CA, US.
2017. (1) Cancer-associated muscle weakness: Role of bone-derived TGFβ (2) Cancer-associated muscle weakness: what’s bone got to do with it?. Invited. San Antonio, TX, US.
2016. Cancer-associated muscle weakness: what’s bone got to do with it?. Invited. Salt Lake City, UT, US.
2016. Bone-derived TGFß mediates muscle weakness associated with breast cancer bone metastases. Invited. Paris, FR.
2016. Bone-derived TGFß mediates muscle weakness associated with breast cancer bone metastases. Invited. Lyon, FR.
2016. Breast cancer-associated muscle weakness: what’s bone got to do with it?. Invited. Dallas, TX, US.
2016. Breast cancer-associated muscle weakness: what’s bone got to do with it?. Invited. Houston, TX, US.
2015. Bone-derived TGFß mediates muscle weakness associated with breast cancer bone metastases. Invited. Madrid, ES.
2015. Cancer-associated muscle weakness: what’s bone got to do with it?. Invited. Urbana, IL, US.
2015. Cancer, muscle and bone: it’s all about the microenvironment. Invited. St. John's, Newfoundland, CA.
2015. Cancer-associated muscle dysfunction: what’s bone got to do with it?. Invited. New York, NY, US.
2015. Prostate cancer bone metastases: role of the microenvironment. Invited. La Jolla, CA, US.
2014. Cancer-associated muscle dysfunction: role of the bone microenvironment. Invited. Los Angeles, CA, US.
2014. Cancer-associated muscle dysfunction: role of the bone microenvironment. Invited. Durham, NC, US.
2014. (1) Molecular mechanisms of bone metastases: implications for therapy (2) Molecular mechanisms of cancer-induced muscle dysfunction. Invited. South Bend, IN, US.
2014. Cancer-associated muscle dysfunction: Role of the bone microenvironment. Invited. Eddendorf, Hamburg, DE.
2014. Cancer-associated muscle weakness: the role of the bone microenvironment. Invited. Tampa, FL, US.
2013. Molecular mechanisms of breast cancer metastases to bone. Invited. Cleveland, OH, US.
2013. Cancer-associated muscle dysfunction: role of the bone microenvironment in ryanodine receptor remodeling. Invited. Tokyo, JP.
2012. Molecular mechanisms of bone metastases: implications for therapy. Invited. Lafayette, IN, US.
2012. TGFß in cancer and bone: Therapeutic opportunities and challenges. Invited. Denver, CO, US.
2011. Remodeling of ryanodine receptor in breast cancer-associated muscle weakness. Invited. New York, NY, US.
2011. Molecular mechanisms of bone metastases: implications for therapy. Invited. Ithaca, NY, US.
2011. Molecular mechanisms of bone metastases: implications for therapy. Invited. Madrid, ES.
2011. Molecular mechanisms of bone metastases: implications for therapy. Invited. New Brunswick, NJ, US.
2011. Molecular mechanisms of bone metastases: implications for therapy. Visiting. New York, NY, US.
2011. TGFß in cancer and bone. Visiting. Grand Rapids, MI, US.
2011. Biology of bone metastases due to breast and prostate cancer. Invited. Madrid, ES.
2010. Molecular mechanisms of TGF-ß signaling in bone metastases: implications for therapy. Invited. Tokushima, JP.
2010. What attracts tumor cells to bone?. Invited. Turku, FI.
2010. TGF-ß: Cancer, Bone and Beyond. Invited. Los Angeles, CA, US.
2010. What makes cancer cells home to bone?. Invited. Paris, FR.
2010. Differential signaling of TGF-ß in the bone microenvironment: Impact on tumor growth. Invited. Paris, FR.
2009. TGF-ß: Cancer, Bone and Beyond. Invited. Indianapolis, IN, US.
2009. (1) TGF-ß: Cancer, Bone and Beyond (2) Role of RANKL/RANK/OPG in skeletal complications of malignancy. Invited. Atlanta, GA, US.
2009. (1) TGF-ß: Cancer, Bone and Beyond (2) Role of RANKL/RANK/OPG in skeletal complications of malignancy. Invited. Pittsburgh, PA, US.
2009. TGF-ß: Cancer, Bone and Beyond. Invited. Leuven, BE.
2009. TGF-beta: Cancer, bone and beyond. Invited. Brisbane, AU.
2009. TGF-beta: Cancer, bone and beyond. Invited. Leiden, NL.
2008. TGF-beta: Cancer, bone and beyond. Visiting. Indianapolis, IN, US.
2008. Biology of bone metastases: Implications for therapy. Invited. Houston, TX, US.
2008. TFGβ: Cancer, bone and beyond. Invited. Montreal, Quebec, CA.
2008. Biology of bone metastases: Therapeutic implications. Invited. New Haven, CT, US.
2008. (1) Biology of bone metastases – Implications for therapy (2) TGFβ: Cancer, bone and beyond. Invited. Norfolk, VA, US.
2008. Biology of Bone Metastases: Implications for Therapy. Invited. Indianapolis, IN, US.
2008. Molecular mechanism of bone metastases: Insight into pathophysiology and treatment. Invited. Tokyo, JP.
2008. TGFβ: Cancer, bone and beyond. Invited. Sapporo, JP.
2008. TGFβ: Cancer, bone and beyond. Visiting. Boston, MA, US.
2008. TGFβ: Cancer, Bone and Beyond. Invited. Ann Arbor, MI, US.
2008. (1) TGFβ: Cancer, bone and beyond (2) The biology of bone metastases: Therapeutic implications. Invited. Pittsburgh, PA, US.
2008. Molecular mechanisms of bone metastases: Implications for therapy. Invited. Dallas, TX, US.
2008. TGFβ in cancer and bone: Friend or foe?. Invited. New Haven, CT, US.
2007. Role of TGF-beta in solid tumor metastases to bone: Implications for therapy. Invited. Nashville, TN, US.
2007. TGFβ signaling in cancer and bone: Friend or foe?. Invited. Birmingham, AL, US.
2007. TGFβ in cancer and bone: Friend or foe?. Invited. Miami, FL, US.
2007. Endothelins: Cancer, bone and beyond. Invited. Nashville, TN, US.
2007. TGFβ in cancer and bone: Friend or foe?. Invited. Rochester, NY, US.
2007. Endothelins in pathologic and normal bone remodeling. Invited. Pittsburgh, PA, US.
2007. Endothelins in pathologic and normal bone remodeling. Visiting. Collegeville, PA, US.
2007. TGFβ signaling in breast cancer bone metastases: Friend or foe?. Invited. Portland, OR, US.
2007. Skeletal health in the cancer patient. Invited. Portland, OR, US.
2007. TGFβ in bone metastases: Pathophysiology to treatment. Invited. New York, NY, US.
2007. TGFβ signaling in cancer metastases to bone: Friend or foe?. Invited. Cleveland, OH, US.
2006. Molecular mechanisms of bone metastases: Insight into therapy. Invited. San Antonio, TX, US.
2006. TGFβ in bone metastases: Pathophysiology to treatment. Visiting. Minneapolis, MN, US.
2006. Pathophysiology of metastases. Invited. San Francisco, CA, US.
2005. Molecular mechanisms of osteoblastic metastases: Implications for therapy. Invited. Niagara Falls, NY, US.
2005. Role of TGFß in breast cancer metastases to bone. Visiting. Boston, MA, US.
2005. Mechanisms of osteolytic metastases to bone: Implications for therapy. Visiting. Philadelphia, PA, US.
2005. Bone metastases: Molecular mechanisms and therapeutic interventions. Visiting. Baltimore, MD, US.
2004. TGFß blockade in bone metastases. Visiting. Cambridge, MA, US.
2004. Molecular mechanisms of bone metastases: Implications for therapy. Invited. New York, NY, US.
2004. Mechanisms of osteoblastic metastases. Invited. Worcester, MA, US.
2004. Endothelin axis in osteoblastic metastases: Implications for skeletal health. Invited. New Haven, CT, US.
2003. Molecular mechanisms of bone metastases. Invited. Birmingham, AL, US.
2003. Cancer migration of tumor cells to bone: The pathology of bone metastases. Invited. Augusta, GA, US.
2003. Role of bisphosphonates in metastatic breast cancer. Invited. Virginia Beach, VA, US.
2002. Disorders of calcium homeostasis. Invited. Victoria, TX, US.
2002. Molecular mechanisms of bone metastases: Implications for therapy. Invited. Salt Lake City, UT, US.
2002. Biology of metastasis in bone injury specific to breast cancer. Invited. Shreveport, LA, US.
2002. New advances in osteoporosis treatment: Role of PTH. Visiting. Greenville, NC, US.
2002. Molecular mechanisms of bone metastases: Implications for therapy. Invited. Long Island, NY, US.
2002. Hypercalcaemia of malignancy. Invited. Greenville, NC, US.
2002. Molecular mechanisms of bone metastases: Implications for therapy. Invited. San Francisco, CA, US.
2002. Molecular mechanisms of bone metastases: Implications for therapy. Invited. Palo Alto, CA, US.
2002. Molecular mechanisms of bone metastases: Implications for therapy. Visiting. South San Francisco, CA, US.
2001. Molecular mechanisms of bone metastases: Implications for therapy. Invited. New York, NY, US.
2001. Molecular mechanisms of osteolytic bone metastases due to breast cancer. Invited. Duarte, CA, US.
2001. Molecular mechanisms of bone metastases: Implications for therapy. Invited. Charlottesville, VA, US.
2001. Molecular mechanisms of osteolytic metastases: Implications for therapy. Invited. New York, NY, US.
2001. Molecular mechanisms of osteolytic metastases: implications for therapy. Invited. New York, NY, US.
2001. PTHrP in malignancy: Hypercalcemia and bone metastases. Invited. Atlanta, GA, US.
2001. Mechanisms of osteolytic bone metastases. Invited. Fayetteville, AR, US.
2001. Molecular mechanisms of bone metastases: osteolytic and osteoblastic. Invited. Richmond, VA, US.
2001. Hypercalcaemia of Malignancy. Visiting. Richmond, VA, US.
2000. Animal models of bone metastases. Invited. Bethesda, MD, US.
2000. Breast cancer metastases to bone: Role of PTHrP and TGFß. Invited. Pittsburgh, PA, US.
2000. PTHrP in malignancy: Hypercalcemia and bone metastases. Invited. Rootstown, OH, US.
2000. Molecular mechanisms of osteolytic metastases: Implications for therapy. Invited. Cleveland, OH, US.
2000. Osteoblastic bone metastases: Role of ET-1. Invited. Pittsburgh, PA, US.
2000. Molecular mechanisms of osteolytic metastases. Visiting. Philadelphia, PA, US.
2000. Molecular mechanisms of osteolytic bone metastases. Invited. Ann Arbor, MI, US.
2000. Role of PTHrP in malignancy. Invited. Detroit, MI, US.
2000. Molecular mechanisms of osteolytic metastases: implications for therapy. Invited. Baltimore, MD, US.
2000. Mechanisms of bone metastases. Invited. Houston, TX, US.
1999. Molecular mechanisms of bone metastases: osteolytic and osteoblastic. Invited. Farmington, CT, US.
1999. Molecular mechanisms of bone metastases. Invited. Montreal, Quebec, CA.
1999. Role of ET-1 in osteoblastic metastases: Mechanisms of bone gain and bone loss. Invited. Meriden, NH, US.
1999. Bone issues in the patient with breast cancer. Invited. San Francisco, CA, US.
1999. Pathogenesis of breast cancer metastases to bone: Role of PTHrP and TGFß. Invited. New Haven, CT, US.
1999. Pathophysiology of bone metastases. Visiting. Oklahoma City, OK, US.
1998. Mechanisms of bone metastases. Invited. Tokyo, JP.
1998. Bone metastases: Mechanisms responsible for osteolytic and osteoblastic lesions. Invited. Osaka, JP.
1998. Breast cancer metastases to bone: Role of PTHrP and TGFß. Invited. Houston, TX, US.
1998. Molecular Mechanisms of Bone Metastases. Invited. Hershey, PA, US.
1998. Mechanisms of bone metastases: osteolytic and osteoblastic. Invited. San Francisco, CA, US.
1998. New insights into the mechanism and treatment of bone metastases. Invited. San Francisco, CA, US.
1998. New insights into the mechanism and treatment of bone metastases. Invited. Fairfield, CA, US.
1998. Mechanisms of bone metastases: osteolytic and osteoblastic. Invited. San Francisco, CA, US.
1998. Breast cancer metastasis to bone: Role of PTHrP and TGFß. Invited. Winston-Salem, NC, US.
1998. Mechanisms of breast cancer metastasis to bone. Invited. Winston-Salem, NC, US.
1997. The role of PTHrP and TGFß in breast cancer metastasis to bone. Invited. Manchester, GB.
1997. The role of TGFß in breast cancer metastasis to bone. Invited. San Antonio, TX, US.
1996. Breast cancer-mediated osteolysis: Role of PTHrP and TGFß. Invited. Galveston, TX, US.
1995. Role of PTHrP in humoral hypercalcemia and breast cancer metastasis to bone. Invited. Kenilworth, NJ, US.
1995. Role of PTHrP in the pathogenesis of breast cancer-mediated bone metastases. Invited. San Antonio, TX, US.
1995. PTHrP in the pathogenesis of breast cancer-mediated osteolysis. Invited. San Francisco, US.
1994. The role of PTHrP in malignancy. Invited. Ann Arbor, MI, US.
1993. Animal models of hypercalcemia. Invited. San Antonio, TX, US.

Less

Grant & Contract Support

Date:	2021 - 2024
Title:	Faculty STARs Award
Funding Source:	University of Texas
Role:	PI

Date:	2020 - 2025
Title:	Cancer Research Prevention Institute of Texas (CPRIT) RR190108 Established Investigator Award
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	PI
ID:	RR190108

Date:	2019 - 2024
Title:	Molecular Mechanisms of Chemotherapy-Induced Cognitive Dysfunction
Funding Source:	NIH/NCI
Role:	Mentor
ID:	R50CA243887

Date:	2018 - 2024
Title:	Role of bone marrow fat on breast cancer growth in bone
Funding Source:	Dive into the Pink
Role:	PI

Selected Publications

Peer-Reviewed Articles

Patil, MD, Wangsiricharoen, S, Lazar, A, Moon, BS, Madewell, JE, Collins, MT, Guise, TA. Approach to determining etiology of hypophosphatemia in a patient with coexisting phosphaturic mesenchymal tumor and fibrous dysplasia. JBMR Plus 9(1), 2025. e-Pub 2025. PMID: 39664934.
Seibert, T, Shi, L, Althouse, S, Hoffman, R, Schneider, BP, Russ, KA, Altherr, CA, Warden, SJ, Guise, TA, Coggan, AR, Ballinger, TJ. Molecular and clinical effects of aromatase inhibitor therapy on skeletal muscle function in early-stage breast cancer. Scientific reports 14(1), 2024. e-Pub 2024. PMID: 38200207.
Plett, PA, Chua, HL, Wu, T, Sampson, CH, Guise, TA, Wright, LE, Pagnotti, GM, Feng, H, Chin-Sinex, HJ, Pike, F, Cox, GN, MacVittie, TJ, Sandusky, GE, Orschell, CM. Effect of Age at Time of Irradiation, Sex, Genetic Diversity, and Granulopoietic Cytokine Radiomitigation on Lifespan and Lymphoma Development in Murine H-ARS Survivors. Radiation research 202(3):580-598, 2024. e-Pub 2024. PMID: 39099001.
Boire, A, Burke, K, Cox, TR, Guise, TA, Jamal-Hanjani, M, Janowitz, T, Kaplan, RN, Lee, R, Swanton, C, Heiden, MG, Sahai, E. Why do patients with cancer die?. Nature Reviews Cancer 24(8):578-589, 2024. e-Pub 2024. PMID: 38898221.
Yang, HS, Pan, W, Wang, Y, Zaydman, MA, Spies, NC, Zhao, Z, Guise, TA, Meng, QH, Wang, F. Generalizability of a Machine Learning Model for Improving Utilization of Parathyroid Hormone-Related Peptide Testing across Multiple Clinical Centers. Clinical chemistry 69(11):1260-1269, 2023. e-Pub 2023. PMID: 37738611.
Liu, Y, Reiken, S, Dridi, H, Yuan, Q, Mohammad, KS, Trivedi, T, Miotto, MC, Wedderburn-Pugh, K, Sittenfeld, L, Kerley, Y, Meyer, JA, Peters, JS, Persohn, SA, Bedwell, AA, Figueiredo, LL, Suresh, S, She, Y, Soni, RK, Territo, PR, Marks, AR, Guise, TA. Targeting ryanodine receptor type 2 to mitigate chemotherapy-induced neurocognitive impairments in mice. Science translational medicine 15(715), 2023. e-Pub 2023. PMID: 37756377.
Trivedi T, Manaa M, John S, Reiken S, Murthy S, Pagnotti GM, Dole NS, She Y, Suresh S, Hain BA, Regan J, Ofer R, Wright L, Robling A, Cao X, Alliston T, Marks AR, Waning DL, Mohammad KS, Guise TA. Zoledronic acid improves bone quality and muscle function in a high bone turnover state. bioRxiv, 2023. e-Pub 2023. PMID: 37333318.
Pagnotti GM, Trivedi T, Wright LE, John SK, Murthy S, Pattyn RR, Willis MS, She Y, Suresh S, Thompson WR, Rubin CT, Mohammad KS, Guise TA. Low-Magnitude Mechanical Signals Combined with Zoledronic Acid Reduce Musculoskeletal Weakness and Adiposity in Estrogen-Deprived Mice. bioRxiv, 2023. e-Pub 2023. PMID: 36993656.
Lui MS, Clemente-Gutierrez U, Vodopivec DM, Chang SL, Shirali AS, Huang BL, Chiang YJ, Fisher SB, Grubbs EG, Guise, TA, Graham PH, Perrier ND. Parathyroidectomy for Normocalcemic Primary Hyperparathyroidism is Associated with Improved Bone Mineral Density Regardless of Postoperative Parathyroid Hormone Levels. World J Surg 47(2):363-370, 2023. e-Pub 2023. PMID: 36195677.
Calvert RD, Fleet JC, Fournier PGJ, Juarez P, Burcham GN, Haverkamp JM, Guise, TA, Ratliff TL, Elzey BD. Monocytic Myeloid-Derived Suppressor Cells from Tumor Tissue Are a Differentiated Cell with Limited Fate Plasticity. Immunohorizons 6(12):790-806, 2022. e-Pub 2022. PMID: 36480485.
Roberts G, Benusiglio PR, Bisseling T, Coit D, Davis JL, Grimes S, Guise, TA, Hardwick R, Harris K, Mansfield PF, Rossaak J, Schreiber KC, Stanich PP, Strong VE, Kaurah P, Group LS. International Delphi consensus guidelines for follow-up after prophylactic total gastrectomy: the Life after Prophylactic Total Gastrectomy (LAP-TG) study. Gastric Cancer 25(6):1094-1104, 2022. e-Pub 2022. PMID: 35831514.
Arellano DL, Juárez P, Verdugo-Meza A, Almeida-Luna PS, Corral-Avila JA, Drescher F, Olvera F, Jiménez S, Elzey BD, Guise, TA, Fournier PGJ. Bone Microenvironment-Suppressed T Cells Increase Osteoclast Formation and Osteolytic Bone Metastases in Mice. J Bone Miner Res 37(8):1446-1463, 2022. e-Pub 2022. PMID: 35635377.
Liu H, He J, Bagheri-Yarmand R, Li Z, Liu R, Wang Z, Bach DH, Huang YH, Lin P, Guise, TA, Gagel RF, Yang J. Osteocyte CIITA aggravates osteolytic bone lesions in myeloma. Nat Commun 13(1):3684, 2022. e-Pub 2022. PMID: 35760800.
Guise, TA, Wysolmerski JJ. Cancer-Associated Hypercalcemia. Reply. N Engl J Med 386(26):2540, 2022. e-Pub 2022. PMID: 35767456.
Trivedi T, Guise, TA. Systemic effects of abnormal bone resorption on muscle, metabolism, and cognition. Bone 154:116245, 2022. e-Pub 2021. PMID: 34718221.
Trivedi T, Pagnotti GM, Guise, TA, Mohammad KS. The Role of TGF-β in Bone Metastases. Biomolecules 11(11), 2021. e-Pub 2021. PMID: 34827641.
Brown JE, Wood SL, Confavreux C, Abe M, Weilbaecher K, Hadji P, Johnson RW, Rhoades JA, Edwards CM, Croucher PI, Juarez P, El Badri S, Ariaspinilla G, D'Oronzo S, Guise TA, Van Poznak C. Management of bone metastasis and cancer treatment-induced bone loss during the COVID-19 pandemic: An international perspective and recommendations. J Bone Oncol 29:100375, 2021. e-Pub 2021. PMID: 34131559.
Nagata Y, Miyagawa K, Ohata Y, Petrusca DN, Pagnotti GM, Mohammad KS, Guise TA, Windle JJ, David Roodman G, Kurihara N. Increased S1P expression in osteoclasts enhances bone formation in an animal model of Paget's disease. J Cell Biochem 122(3-4):335-348, 2021. e-Pub 2021. PMID: 33107091.
Patterson AM, Wu T, Chua HL, Sampson CH, Fisher A, Singh P, Guise TA, Feng H, Muldoon J, Wright L, Plett PA, Pelus LM, Orschell CM. Optimizing and Profiling Prostaglandin E2 as a Medical Countermeasure for the Hematopoietic Acute Radiation Syndrome. Radiat Res 195(2):115-127, 2021. e-Pub 2021. PMID: 33302300.
Yi X, Wright LE, Pagnotti GM, Uzer G, Powell KM, Wallace JM, Sankar U, Rubin CT, Mohammad K, Guise TA, Thompson WR. Mechanical suppression of breast cancer cell invasion and paracrine signaling to osteoclasts requires nucleo-cytoskeletal connectivity. Bone Res 8(1):40, 2020. e-Pub 2020. PMID: 33298883.
Xu W, Yang Y, Hu Z, Head M, Mangold KA, Sullivan M, Wang CH, Saha P, Gulukota K, Jr HD, Guise T, Prabhakar BS, Kaul K, Schreiber H, Seth P. LyP-1-modified oncolytic adenoviruses targeting transforming growth factor β inhibit tumor growth and metastases and augment immune checkpoint inhibitor therapy in breast cancer mouse models. Hum Gene Ther 31(15-16):863-880, 2020. e-Pub 2020. PMID: 32394753.
Morris MJ, Corey E, Guise TA, Gulley JL, Kevin Kelly W, Quinn DI, Scholz A, Sgouros G. Radium-223 mechanism of action: implications for use in treatment combinations. Nat Rev Urol 16(12):745-756, 2019. e-Pub 2019. PMID: 31712765.
Pagnotti GM, Styner M, Uzer G, Patel VS, Wright LE, Ness KK, Guise TA, Rubin J, Rubin CT. Combating osteoporosis and obesity with exercise: leveraging cell mechanosensitivity. Nat Rev Endocrinol 15(6):339-355, 2019. e-Pub 2019. PMID: 30814687.
Saito H, Gasser A, Bolamperti S, Maeda M, Matthies L, Jähn K, Long CL, Schlüter H, Kwiatkowski M, Saini V, Pajevic PD, Bellido T, van Wijnen AJ, Mohammad KS, Guise TA, Taipaleenmäki H, Hesse E. TG-interacting factor 1 (Tgif1)-deficiency attenuates bone remodeling and blunts the anabolic response to parathyroid hormone. Nat Commun 10(1):1354, 2019. e-Pub 2019. PMID: 30902975.
Singh P, Hoggatt J, Kamocka MM, Mohammad KS, Saunders MR, Li H, Speth J, Carlesso N, Guise TA, Pelus LM. Neuropeptide Y regulates a vascular gateway for hematopoietic stem and progenitor cells. J Clin Invest 127(12):4527-4540, 2017. e-Pub 2017. PMID: 29130940.
Regan JN, Mikesell C, Reiken S, Xu H, Marks AR, Mohammad KS, Guise TA, Waning DL. Osteolytic Breast Cancer Causes Skeletal Muscle Weakness in an Immunocompetent Syngeneic Mouse Model. Front Endocrinol 19(8):358, 2017. e-Pub 2017. PMID: 29312148.
Ross MH, Esser AK, Fox GC, Schmieder AH, Yang X, Hu G, Pan D, Su X, Xu Y, Novack DV, Walsh T, Colditz GA, Lukaszewicz GH, Cordell E, Novack JS, Fitzpatrick JAJ, Waning DL, Mohammad KS, Guise TA, Lanza GM, Weilbaecher KN. Bone-induced expression of integrin β3 enables targeted nanotherapy of breast cancer metastases. Cancer Res 77(22):6299-6312, 2017. e-Pub 2017. PMID: 28855208.
Juárez P, Fournier PGJ, Mohammad KS, McKenna RC, Davis HW, Peng XH, Niewolna M, Mauviel A, Chirgwin JM, Guise TA. Halofuginone inhibits TGF-β/BMP signaling and in combination with zoledronic acid enhances inhibition of breast cancer bone metastasis. Oncotarget 8(49):86447-86462, 2017. e-Pub 2017. PMID: 29156807.
Trivedi T, Zheng Y, Fournier PGJ, Murthy S, John S, Schillo S, Dunstan CR, Mohammad KS, Zhou H, Seibel MJ, Guise TA. The vitamin D receptor is involved in the regulation of human breast cancer cell growth via a ligand-independent function in cytoplasm. Oncotarget 8(16):26687-26701, 2017. e-Pub 2017. PMID: 28460457.
Wright LE, Harhash AA, Kozlow WM, Waning DL, Regan JN, She Y, John SK, Murthy S, Niewolna M, Marks AR, Mohammad KS, Guise TA. Aromatase inhibitor-induced bone loss increases the progression of estrogen receptor-negative breast cancer in bone and exacerbates muscle weakness in vivo. Oncotarget 8(5):8406-8419, 2017. e-Pub 2017. PMID: 28039445.
Khan AA, Morrison A, Kendler DL, Rizzoli R, Hanley DA, Felsenberg D, McCauley LK, O'Ryan F, Reid IR, Ruggiero SL, Taguchi A, Tetradis S, Watts NB, Brandi ML, Peters E, Guise T, Eastell R, Cheung AM, Morin SN, Masri B, Cooper C, Morgan SL, Obermayer-Pietsch B, Langdahl BL, Dabagh RA, Davison KS, Sándor GK, Josse RG, Bhandari M, El Rabbany M, Pierroz DD, Sulimani R, Saunders DP, Brown JP, Compston J. International Task Force on Osteonecrosis of the Jaw. Case-Based Review of Osteonecrosis of the Jaw (ONJ) and Application of the International Recommendations for Management From the International Task Force on ONJ. J Clin Densitom 20(1):8-24, 2017. e-Pub 2017. PMID: 27956123.
Bonetto A, Kays JK, Parker VA, Matthews RR, Barreto R, Puppa MJ, Kang KS, Carson JA, Guise TA, Mohammad KS, Robling AG, Couch ME, Koniaris LG, Zimmers TAA. Differential Bone Loss in Mouse Models of Colon Cancer Cachexia. Front Physiol 11(7):679, 2017. e-Pub 2017. PMID: 28123369.
Zhang P, Xing C, Rhodes SD, He Y, Deng K, Li Z, He F, Zhu C, Nguyen L, Zhou Y, Chen S, Mohammad KS, Guise TA, Abdel-Wahab O, Xu M, Wang QF, Yang FC. Loss of Asxl1 Alters Self-Renewal and Cell Fate of Bone Marrow Stromal Cell, Leading to Bohring-Opitz-like Syndrome in Mice. Stem Cell Reports 6(6):914-925, 2016. e-Pub 2016. PMID: 27237378.
Teramachi J, Nagata Y, Mohammad K, Inagaki Y, Ohata Y, Guise T, Michou L, Brown JP, Windle JJ, Kurihara N, Roodman GD. Measles virus nucleocapsid protein increases osteoblast differentiation in Paget's disease. J Clin Invest 126(3):1012-1022, 2016. e-Pub 2016. PMID: 26878170.
Edwards BJ, Gradishar WJ, Smith ME, Pacheco JA, Holbrook J, McKoy JM, Nardone B, Tica S, Godinez-Puig V, Rademaker AW, Helenowski IB, Bunta AD, Stern PH, Rosen ST, West DP, Guise TA. Elevated incidence of fractures in women with invasive breast cancer. Osteoporos Int 27(2):499-507, 2016. e-Pub 2016. PMID: 26294292.
Yang Y, Xu WW, Neill T, Hu Z, Wang CH, Xiao X, Stock S, Guise T, Yun CO, Brendler CB, Iozzo RV, Seth P. Systemic Delivery of an Oncolytic Adenovirus Expressing Decorin for the Treatment of Breast Cancer Bone Metastases. Hum Gene Ther 26(12):813-825, 2015. e-Pub 2015. PMID: 26467629.
Waning DL, Mohammad KS, Reiken S, Xie W, Andersson DC, John S, Chiechi A, Wright LE, Umanskaya A, Niewolna M, Trivedi T, Charkhzarrin S, Khatiwada P, Wronska A, Haynes A, Benassi MS, Witzmann FA, Roodman GD, Marks AR, Guise TA. Excess TGFβ mediates muscle weakness associated with bone metastases in mice. Nature Medicine 21(11):1262-1271, 2015. e-Pub 2015. PMID: 26457758.
Rhodes SD, Yang H, Dong R, Menon K, He Y, Li Z, Chen S, Staser KW, Jiang L, Wu X, Yang X, Peng X, Mohammad KS, Guise TA, Xu M, Yang FC. Nf1 Haploinsufficiency Alters Myeloid Lineage Commitment and Function, Leading to Deranged Skeletal Homeostasis. J Bone Miner Res 30(10):1840-1851, 2015. e-Pub 2015. PMID: 25917016.
Stayrook K, Mack JK, Cerabona D, Edwards DF, Bui HH, Niewolna M, Fournier PGJ, Mohammad KS, Waning D, Guise TA. TGFβ-Mediated Induction of SphK1 as a Potential Determinant in Human MDA-MB-231 Breast Cancer Cell Bone Metastasis. Bonekey Rep 8(4):719, 2015. e-Pub 2015. PMID: 26157579.
Wright LE, Buijs JT, H-S K, Coats LE, Anne M Scheidler AM, John SK, She Y, Murthy S, Ma N, Chin-Sinex HJ, Bellido TM, Bateman TA, Mendonca MS, Mohammad KS, Guise TA. Single-limb irradiation induces local and systemic bone loss in a murine model. J Bone Miner Res 30(7):1268-1279, 2015. e-Pub 2015. PMID: 25588731.
Fournier PGJ, Juárez P, Jiang G, Clines GA, Niewolna M, H-S K, Walton HW, Peng X, Liu Y, Mohammad KS, Wells CD, Chirgwin JM, Guise TA. The TGFβ Signaling Regulator PMEPA1 Suppresses Prostate Cancer Metastases to Bone. Cancer Cell 27(6):809-821, 2015. e-Pub 2015. PMID: 25982816.
Santulli G, Pagano G, Sardu C, Xie W, Reiken S, Luca D'Ascia S, Cannone M, Marziliano N, Trimarco B, Guise TA, Lacampagne A, Marks AR. Calcium release channel RyR2 regulates insulin release and glucose homeostasis. J Clin Invest 125(5):1968-1978, 2015. e-Pub 2015. PMID: 25844899.
Wu C, Rankin EB, Castellini L, Fernandez-Alcudia J, LaGory EL, Andersen R, Rhodes SD, Wilson TL, Mohammad KS, Castillo AB, Guise TA, Schipani E, Giaccia AJ. Oxygen-sensing PHDs regulate bone homeostasis through the modulation of osteoprotegerin. Genes Dev 29(8):817-831, 2015. e-Pub 2015. PMID: 25846796.
Buijs JT, Matula KM, Cheung H, Kruithof-de Julio M, van der Mark M, Snoeks TJ, Cohen R, Corver WE, Mohammad KS, Jonkers J, Guise TA, van der Pluijm G. Spontaneous Bone Metastases in a Preclinical Orthotopic Model of Invasive Lobular Carcinoma; the Effect of Pharmacological Targeting TGFβ receptor I kinase. J Pathol 235(5):745-759, 2015. e-Pub 2015. PMID: 25421310.
Rhodes SD, Zhang W, Yang D, Yang H, Chen S, Wu X, Li X, Yang X, Mohammad KS, Guise TA, Bergner AL, Stevenson DA, Yang FC. Dystrophic spinal deformities in a neurofibromatosis type 1 murine model. PloS ONE 10(3):e0119093, 2015. e-Pub 2015. PMID: 25786243.
Khan AA, Morrison A, Hanley DA, Felsenberg D, McCauley LK, O'Ryan F, Reid IR, Ruggiero SL, Taguchi A, Tetradis S, Watts NB, Brandi ML, Peters E, Guise T, Eastell R, Cheung AM, Morin SN, Masri B, Cooper C, Morgan SL, Obermayer-Pietsch B, Langdahl BL, Al Dabagh R, Davison KS, Kendler DL, Sándor GK, Josse RG, Bhandari M, El Rabbany M, Pierroz DD, Sulimani R, Saunders DP, Brown JP, Compston J, the Jaw ITFOOO. Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. J Bone Miner Res 30(1):3-23, 2015. e-Pub 2015. PMID: 25414052.
Siclari VA, Mohammad KS, Tompkins DR, Davis H, McKenna CR, Peng X, Wessner LL, Niewolna M, Guise TA, Suvannasankha A, Chirgwin JM. Tumor-expressed adrenomedullin accelerates breast cancer bone metastasis. Breast Cancer Res 16(6):458, 2014. e-Pub 2014. PMID: 25439669.
Xu W, Zhang Z, Yang Y, Hu Z, Wang CH, Morgan M, Wu Y, Hutten R, Xiao X, Stock S, Guise T, Prabhakar BS, Brendler C, Seth P. Ad5/48 Hexon Oncolytic Virus Expressing sTGFβRIIFc Produces Reduced Hepatic and Systemic Toxicities and Inhibits Prostate Cancer Bone Metastases. Mol Ther 22(8):1504-1517, 2014. e-Pub 2014. PMID: 24791939.
Waning DL, Guise TA. Molecular Mechanisms of Bone Metastasis and Associated Muscle Weakness. Clin Cancer Res 20(12):3071-3077, 2014. e-Pub 2014. PMID: 24677373.
Rhodes SD, Wu X, He Y, Chen S, Yang H, Staser KW, Wang J, Zhang P, Jiang C, Yokota H, Dong R, Peng X, Yang X, Murthy S, Azhar M, Mohammad KS, Xu M, Guise TA, Yang FC. Hyperactive transforming growth factor-β1 signaling potentiates skeletal defects in a neurofibromatosis type 1 mouse model. J Bone Miner Res 28(12):2476-2489, 2013. e-Pub 2013. PMID: 23703870.
Casimiro S, Mohammad KS, Pires R, Tato-Costa J, Alho I, Teixeira R, Carvalho A, Ribeiro S, Lipton A, Guise TA, Costa L. RANKL/RANK/MMP-1 Molecular Triad Contributes to the Metastatic Phenotype of Breast and Prostate Cancer Cells In Vitro. PloS ONE 8(5):e63153, 2013. e-Pub 2013. PMID: 23696795.
Wright LE, Frye JB, Lukefahr AL, Timmermann BN, Mohammad KS, Guise TA, Funk JL. Curcuminoids Block TGF-β Signaling in Human Breast Cancer Cells and Limit Osteolysis in a Murine Model of Breast Cancer Bone Metastasis. J Nat Prod 76(3):316-321, 2013. e-Pub 2013. PMID: 23145932.
Hoggatt J, Mohammad KM, Singh P, Hoggatt AF, Chitteti BR, Speth JM, Hu P, Poteat BA, Stilger KN, Ferraro F, Silberstein L, Wong FK, Farag SS, Czader M, Milne GL, Breyer RM, Serezani CH, Scadden DT, Guise TA, Srour EF, Pelus LM. Differential Stem and Progenitor Trafficking by Cyclooxygenase/Prostaglandin E2. Nature 495(7441):365-369, 2013. e-Pub 2013. PMID: 23485965.
Juárez P, Mohammad KS, Yin JJ, Fournier PG, McKenna RC, Davis HW, Peng XH, Niewolna M, Javelaud D, Chirgwin JM, Mauviel A, Guise TA. Halofuginone inhibits the establishment and progression of melanoma bone metastases. Cancer Res 72(23):6247-6256, 2012. e-Pub 2012. PMID: 23002206.
Hadji P, Gnant M, Body JJ, Bundred NJ, Brufsky A, Coleman RE, Guise TA, Lipton A, Aapro MS. Cancer treatment-induced bone loss in premenopausal women: A need for therapeutic intervention?. Cancer Treat Res 38(6):798-806, 2012. e-Pub 2012. PMID: 22429722.
Hu Z, Gupta J, Zhang Z, Gerseny H, Berg A, Chen YJ, Zhang Z, Du H, Brendler CB, Xiao X, Pienta KJ, Guise T, Lee C, Stern PH, Stock S, Seth P. Systemic Delivery of Oncolytic Adenoviruses Targeting Transforming Growth Factor-β Inhibits Established Bone Metastasis in a Prostate Cancer Mouse Model. Hum Gene Ther 23(8):871-882, 2012. e-Pub 2012. PMID: 22551458.
Pollari S, Käkönen RS, Mohammad KS, Rissanen JP, Halleen JM, Wärri A, Nissinen L, Pihlavisto M, Marjamäki A, Perälä M, Guise TA, Kallioniemi O, Käkönen SM. Heparin-like polysaccharides reduce osteolytic bone destruction and tumor growth in a mouse model of breast cancer bone metastasis. Mol Cancer Res 10(5):597-604, 2012. e-Pub 2012. PMID: 22522458.
Cao L, Shao M, Schilder J, Guise T, Mohammad KS, Matei D. Tissue transglutaminase links TGF-β, epithelial to mesenchymal transition and a stem cell phenotype in ovarian cancer. Oncogene 31(20):2521-2534, 2012. e-Pub 2012. PMID: 21963846.
Buijs JT, Stayrook KR, Guise TA. The role of TGF-β in bone metastasis: novel therapeutic perspectives. Bonekey Rep 1:96, 2012. e-Pub 2012. PMID: 23951484.
He Y, Rhodes SD, Chen S, Wu X, Yuan J, Yang X, Jiang L, Li X, Takahashi N, Xu M, Mohammad KS, Guise TA, Yang FC. c-Fms Signaling Mediates Neurofibromatosis Type-1 Osteoclast Gain-In-Functions. PloS ONE 7(11):e46900, 2012. e-Pub 2012. PMID: 23144792.
Nickerson NK, Mohammad KS, Gilmore JL, Crismore E, Bruzzaniti A, Guise TA, Foley J. Decreased Autocrine EGFR Signaling in Metastatic Breast Cancer Cells Inhibits Tumor Growth in Bone and Mammary Fat Pad. PloS ONE 7(1):e30255, 2012. e-Pub 2012. PMID: 22276166.
Hadji P, Aapro MS, Body JJ, Bundred NJ, Brufsky A, Coleman RE, Gnant M, Guise T, Lipton A. Management of aromatase inhibitor-associated bone loss in postmenopausal women with breast cancer: practical guidance for prevention and treatment. Ann Oncol 22(12):2546-2555, 2011. e-Pub 2011. PMID: 21415233.
Buijs JT, Juarez P, Guise TA. Therapeutic Strategies to Target TGFß in the Treatment of Bone Metastases. Curr Pharm Biotechnol 12(12):2121-2137, 2011. e-Pub 2011. PMID: 21619539.
Buijs JT, Stayrook KR, Guise TA. TGF-β in the Bone Microenvironment: Role in Breast Cancer Metastases. Cancer Microenviron 4(3):261-81, 2011. e-Pub 2011. PMID: 21748439.
Clines GA, Mohammad KS, Grunda JM, Clines KL, Niewolna M, McKenna CR, McKibbin CR, Yanagisawa M, Suva LJ, Chirgwin JM, Guise TA. Regulation of postnatal trabecular bone formation by the osteoblast endothelin A receptor. J Bone Miner Res 26(10):2523-2536, 2011. e-Pub 2011. PMID: 21698666.
Weilbaecher, K, Guise TA, McCauley LM. Cancer to bone: the fatal attraction. Nature Reviews Cancer 11(6):411-425, 2011. e-Pub 2011. PMID: 21593787.
Liang H, Ma SY, Mohammad K, Guise TA, Balian G, Shen FH. The reaction of bone to tumor growth from human breast cancer cells in a rat spine single metastasis model. Spine 36(7):497-504, 2011. e-Pub 2011. PMID: 21422981.
Edwards BJ, Raisch DW, Shankaran V, McKoy JM, Gradishar W, Bunta AD, Samaras AT, Boyle SN, Bennett CL, West DP, Guise TA. Cancer therapy associated bone loss: implications for hip fractures in mid-life women with breast cancer. Clin Cancer Res 17(3):560-568, 2011. e-Pub 2011. PMID: 21288927.
Wu X, Chen S, He Y, Rhodes SD, Mohammad KS, Li X, Yang X, Jiang L, Nalepa G, Snider P, Robling AG, Clapp DW, Conway SJ, TA <, Yang FC. The haploinsufficient hematopoietic microenvironment is critical to the pathological fracture repair in murine models of neurofibromatosis type 1. PloS ONE 6(9):e24917, 2011. e-Pub 2011. PMID: 21980365.
Guise TA, Brufsky A, Coleman RE. Understanding and optimizing bone health in breast cancer. Curr Med Res Opin 26(Suppl 3):3-20, 2010. e-Pub 2010. PMID: 21050131.
Mohammad KS, Javelaud D, Fournier PG, Niewolna M, McKenna CR, Peng XH, Duong V, Dunn LK, Mauviel A, Guise TA. The Transforming Growth Factor-{beta} Receptor I Kinase Inhibitor SD-208 Reduces the Development and Progression of Melanoma Bone Metastases. Cancer Res 71(1):175-184, 2010. e-Pub 2010. PMID: 21084275.
Hu Z, Zhang Z, Guise T, Seth P. Systemic Delivery of an Oncolytic Adenovirus Expressing Soluble TGFß Receptor II-Fc Fusion Protein Can Inhibit Breast Cancer Bone Metastasis in a Mouse Model. Hum Gene Ther 21(11):1623-1629, 2010. e-Pub 2010. PMID: 20712434.
Guise, TA. Examining the metastatic niche: targeting the microenvironment. Semin Oncol 37(Suppl 2):S2-14, 2010. e-Pub 2010. PMID: 21111245.
Coenegrachts L, Maes C, Torrekens S, Van Looveren R, Mazzone M, Guise TA, Bouillon R, Stassen JM, Carmeliet P, Carmeliet G. Anti-placental growth factor reduces bone metastasis by blocking tumor cell engraftment and osteoclast differentiation. Cancer Res 70(16):6537-6547, 2010. e-Pub 2010. PMID: 20682798.
Juarez, P, Guise, TA. TGFß in cancer and bone: Implications for treatment of bone metastases. Bone 48(1):23-29, 2010. e-Pub 2010. PMID: 20699127.
Alexaki VI, Javelaud, D, Van Kempen LCL, Mohammad KS, Dennler S, Luciani F, Hoek K, Juarez P, Goydos JS, Sibon C, Bertolotto C, Verrecchia F, Saule S, Delmas V, Ballotti R, Larue L, Saiag P, Guise, TA, Mauviel A. GLI2, A TGF-ß-inducible target, promotes melanoma invasion and metastasis. J Natl Cancer Inst 102(15):1148-1159, 2010. e-Pub 2010. PMID: 20660365.
Coleman RE, Lipton A, Roodman GD, Guise TA, Boyce BF, Brufsky AM, Clezardin P, Croucher PI, Gralow JR, Hadji P, Holen I, Mundy GR, Smith MR, Suva LJ. Metastasis and bone loss: Advancing treatment and prevention. Cancer Treat Rev 36(8):612-620, 2010. e-Pub 2010. PMID: 20478658.
Pollari S, Kakonen SM, Edgren H, Wolf M, Kohonen P, Sara H, Guise T, Nees M, Kallioniemi O. Enhanced serine production by bone metastatic breast cancer cells stimulate osteoclastogenesis. Breast Cancer Res Treat 125(2):421-430, 2010. e-Pub 2010. PMID: 20352489.
Juárez P, Guise TA. Tgf-Beta pathway as a therapeutic target in bone metastases. Curr Pharm Des 16(11):1301-12, 2010. e-Pub 2010. PMID: 20166977.
Akech J, Wixted JJ, Bedard K, van der Deen M, Hussain S, Guise TA, van Wijnen AJ, Stein JL, Languino LR, Altieri DC, Pratap J, Keller E, Stein GS, Lian JB. Runx2 association with progression of prostate cancer in patients: mechanisms mediating bone osteolysis and osteoblastic metastatic lesions. Oncogene 29(6):811-821, 2009. e-Pub 2009. PMID: 19915614.
Casimiro S, Guise TA, Chirgwin J. The critical role of the bone microenvironment in cancer metastases. Mol Cell Endocrinol 310(1-2):71-81, 2009. e-Pub 2009. PMID: 19616059.
Hu Z, Robbins JS, Pister A, Zafar MB, Zhang ZW, Gupta J, Lee KJ, Neuman K, Yun CO, Guise T, Seth P. A modified hTERT promoter-directed oncolytic adenovirus replication with concurrent inhibition of TGFß signaling for breast cancer therapy. Cancer Gene Ther 17(4):235-243, 2009. e-Pub 2009. PMID: 19798122.
Dunn LK, Mohammad KS, Fournier PGJ, McKenna CR, Davis HW, Niewolna M, Peng XP, Chirgwin JM, Guise TA. Hypoxia and TGF-β Drive Breast Cancer Bone Metastases through Parallel Signaling Pathways in Tumor Cells and the Bone Microenvironment. PloS ONE 4(9):e6896, 2009. e-Pub 2009. PMID: 19727403.
Mohammad KS, Chen C, Balooch G, Stebbins E, McKenna CR, Walton H, Niewolna M, Peng X, Nguyen D, Ionova-Martin SS, Bracey JW, Hogue WR, Wong DH, Ritchie RO, Suva LJ, Derynck R, Guise TA, Alliston T. Pharmacologic inhibition of the TGF-β type 1 receptor kinase has anabolic and anti-catabolic effects on bone. PloS ONE 4(4):e5275, 2009. e-Pub 2009. PMID: 19357790.
Guise TA, O’Keefe R, Randall L, Terek RM. Molecular biology and therapeutics in musculoskeletal oncology. J Bone Joint Surg Am 91:724-732, 2009. e-Pub 2009. PMID: 19255238.
Brown, SA, Guise, TA. Cancer treatment-related bone disease. Crit Rev Eukaryot Gen Expr 19(1):47-60, 2009. e-Pub 2009. PMID: 19191756.
Coleman RE, Guise TA, Lipton A, Roodman GD, Berenson JR, Body JJ, Boyce BF, Calvi LM, Hadji P, McCloskey EV, Saad F, Smith MR, Suva LJ, Taichman RS, Vessella RL, Weilbaecher KN. Advancing treatment for metastatic bone cancer: consensus recommendations from the Second Cambridge Conference. Clin Cancer Res 14(20):6387-6395, 2008. e-Pub 2008. PMID: 18927277.
for Bone AS, the Jaw MRTFOOO, Khosla S, Burr D, Cauley J, Dempster DW, Ebeling PR, Felsenberg D, Gagel RF, Gilsanz V, Guise T, Koka S, McCauley LK, McGowan J, McKee MD, Mohla S, Pendrys DG, Raisz LG, Ruggiero SL, Shafer DM, Shum L, Silverman SL, Van Poznak CH, Watts N, Woo SB, Shane E. Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J Oral Maxillofac Surg 66(6):1320-1321, 2008. e-Pub 2008. PMID: 18486811.
Hadji P, Body JJ, Aapro MS, Brufsky A, Coleman RE, Guise T, Lipton A, Tubiana-Hulin M. Practical guidance for the management of aromatase inhibitor-associated bone loss. Ann Oncol 19(8):1407-1416, 2008. e-Pub 2008. PMID: 18448451.
Clines GA, Guise TA. Molecular mechanisms and treatment of bone metastasis. Expert Rev Mol Med 10(e7), 2008. e-Pub 2008. PMID: 18321396.
Akhtari M, Mansuri J, Newman KA, Guise T, Seth P. Biology of breast cancer bone metastasis. Cancer Biol Ther 7(1):3-9, 2008. e-Pub 2008. PMID: 18059174.
Brown SA, Clines GA, Guise TA. Local effects of malignancy on bone. Curr Opin Endocrinol Diabetes Obes 14(6):3-9, 2007. e-Pub 2007. PMID: 17982348.
Khosla S, Burr D, Cauley J, Dempster DW, Ebeling PR, Felsenberg D, Gagel RF, Gilsanz V, Guise T, Koka S, McCauley LK, McGowan J, McKee MD, Mohla S, Pendrys, DG, Raisz LG, Ruggiero SL, Shafer DM, Shum L, Silverman SL, Van Poznak CH, Watts N, Woo SB, Shane E. Bisphosphonate-associated osteonecrosis of the jaw: Report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 22(10):1479-1491, 2007. e-Pub 2007. PMID: 17663640.
Kingsley LA, Fournier PG, Chirgwin JM, Guise TA. Molecular biology of bone metastasis. Mol Cancer Ther 6(10):2609-2617, 2007. e-Pub 2007. PMID: 17938257.
Guise TA, Oefelein MG, Eastham JA, Cookson MS, Higano CS, Smith MR. Estrogenic side effects of androgen deprivation therapy. Rev Urol 9(4):163-180, 2007. e-Pub 2007. PMID: 18231613.
Brown, SA, Guise, TA. Cancer-associated bone disease. Curr Osteoporos Rep 5(3):120-127, 2007. e-Pub 2007. PMID: 17925193.
Fournier PGJ, Guise TA. BMP7: A New Bone Metastases Prevention?. Am J Pathol 171(3):739-743, 2007. e-Pub 2007. PMID: 17690188.
Brown SA, Guise TA. Drug insight: the use of bisphosphonates for the prevention and treatment of osteoporosis in men. Nat Clin Pract Urol 4(6):310-320, 2007. e-Pub 2007. PMID: 17551535.
Kingsley LA, Chirgwin JM, Guise TA. Breaking new ground to build bone. Proc Natl Acad Sci USA 104(26):10753-10754, 2007. e-Pub 2007. PMID: 17581868.
Javelaud D, Mohammad KS, McKenna CR, Fournier P, Luciani F, Niewolna M, André J, Delmas V, Larue L, Guise TA, Mauviel A. Stable overexpression of Smad7 in human melanoma cells impairs bone metastasis. Cancer Res 67(5):2317-2324, 2007. e-Pub 2007. PMID: 17332363.
Bartholin L, Wessner L, Chirgwin JM, Guise, TA. The human Cyr61 gene is a transcriptional target of transforming growth factor ß. Cancer Lett 246(1-2):230-236, 2007. e-Pub 2007. PMID: 16616811.
Clines GA, Mohammad KS, Bao Y, Stephens OW, Suva LJ, Jr SJ, Fox JW, Chirgwin JM, Guise TA. Dickkopf homolog 1 mediates endothelin-1-stimulated new bone formation. Mol Endocrinol 21(2):486-498, 2007. e-Pub 2007. PMID: 17068196.
Seth P, Wang ZG, Pister A, Zafar MB, Kim S, Guise T, Wakefield L. Development of oncolytic adenovirus armed with a fusion of soluble transforming growth factor-beta receptor II and human immunoglobulin Fc for breast cancer therapy. Hum Gene Ther 17(11):1152-1160, 2006. e-Pub 2006. PMID: 17032151.
Guise, TA. Bone loss and fracture risk associated with cancer therapy. Oncologist 11(10):1121-1131, 2006. e-Pub 2006. PMID: 17110632.
Guise TA, Mohammad KS, Clines G, Stebbins EG, Wong DH, Higgins LS, Vessella R, Corey E, Padalecki S, Suva L, Chirgwin JM. Basic mechanisms responsible for osteolytic and osteoblastic bone metastases. Clin Cancer Res 12(20):6213s-6216s, 2006. e-Pub 2006. PMID: 17062703.
Lipton A, Berenson JR, Body JJ, Boyce BF, Bruland OS, Carducci MA, Cleeland CS, Clohisy DR, Coleman RE, Cook RJ, Guise TA, Pearse RN, Powles TJ, Rogers MJ, Roodman GD, Smith MR, Suva LJ, Vessella RL, Weilbaecher KN, King L. Advances in treating metastatic bone cancer: Summary statement for the First Cambridge Conference. Clin Cancer Res 12(20):6209s-6212s, 2006. e-Pub 2006. PMID: 17062702.
Guise, TA. Do markers of bone turnover predict clinical outcome in patients with bone metastases?. Nat Clin Pract Endocrinol Metab 2(5):258-259, 2006. e-Pub 2006. PMID: 16932296.
Theriault RL, Biermann JS, Brown E, Brufsky A, Demers L, Grewal RK, Guise T, Jackson R, McEnery K, Podoloff D, Ravdin P, Shapiro CL, Smith M, Van Poznak CH. NCCN Task Force Report: Bone health and cancer care. J Natl Compr Canc Netw 4 Suppl(2):S1-20, 2006. e-Pub 2006. PMID: 16737674.
Zudaire E, Martinez A, Garayoa M, Pio R, Kaur G, Woolhiser MR, Metcalfe DD, Hook WA, Siraganian RP, Guise TA, Chirgwin JM, Cuttitta F. Adrenomedullin is a cross-talk molecule that regulates tumor and mast cell function during human carcinogenesis. Am J Pathol 168(1):280-291, 2006. e-Pub 2006. PMID: 16400030.
Bendre, MS, Margulies, AG, Walser, B, Akel, NS, Bhattacharrya, S, Skinner, RA, Swain, F, Ramani, V, Mohammad, KS, Wassner, LL, Martinez, A, Guise, TA, Chirgwin, JM, Gaddy, D, Suva, LJ. Tumor-derived interleukin-8 stimulates osteolysis independent of the receptor activator of nuclear factor-kappaB ligand pathway. Cancer Res 65(23):11001-11009, 2005. e-Pub 2005. PMID: 16322249.
Clines, GA, Guise, TA. Hypercalcaemai of malignancy and basic research on mechanisms responsible for osteolytic and osteoblastic metastasis to bone. Endocr Relat Cancer 12(3):549-583, 2005. e-Pub 2005. PMID: 16172192.
Titus B, Jr FH, Conaway M, Ching K, Guise T, Chirgwin J, Hampton G, Theodorescu D. Endothelin axis is a target of the lung metastasis suppressor gene RhoGDI2. Cancer Res 65(16):7320-7327, 2005. e-Pub 2005. PMID: 16103083.
Kozlow W, Guise TA. Breast cancer metastasis to bone: mechanisms of osteolysis and implications for therapy. J Mammary Gland Biol Neoplasia 10(2):169-180, 2005. e-Pub 2005. PMID: 16025223.
Aris RM, Merkel PA, Bachrach LK, Borowitz DS, Boyle MP, Elkin SL, Guise TA, Hardin DS, Haworth CS, Holick MF, Joseph PM, O’Brien K, Tullis E, Watts NB, White TB. Consensus Conference Report: Guide to bone health and disease in cystic fibrosis. J Clin Endocrinol Metab 80(3):1888-1896, 2005. e-Pub 2005. PMID: 15613415.
Chirgwin, JM, Mohammad, KS, Guise, TA. Tumor-bone cellular interactions in skeletal metastases. J Musculoskelet Neuronal Interact 4(3):308-318, 2004. e-Pub 2004. PMID: 15615499.
Diamond TH, Higano CS, Smith MR, Guise TA, Singer FR. Osteoporosis in men with prostate cancer receiving androgen deprivation therapy: recommendations for diagnosis and therapies. Cancer 100(5):892-899, 2004. e-Pub 2004. PMID: 14983482.
Maier B, Gluba W, Bernier B, Turner T, Mohammad K, Guise TA, Sutherland A, Thorner M, Scrable H. Modulation of mammalian life-span by the short isoform of p53. Genes Dev 18(3):306-319, 2004. e-Pub 2004. PMID: 14871929.
Chirgwin JM, Guise TA. Interactions between tumor and bone alter the phenotypes of both. J Musculoskelet Neuronal Interact 3(4):278-81; discussion 292-4, 2003. e-Pub 2003. PMID: 15758298.
Mohammad KS, Guise TA. Mechanisms of osteoblastic metastases: role of endothelin-1. Clinical Orthop Relat Res (415 Suppl):S67-74, 2003. e-Pub 2003. PMID: 14600594.
O’Keefe RJ, Guise TA. Molecular mechanisms of bone metastasis and therapeutic implications. Clinical Orthop Relat Res (415 Suppl):S100-104, 2003. e-Pub 2003. PMID: 14600598.
Guise TA, Chirgwin JM. Role of bisphosphonates in prostate cancer bone metastases. Sem Oncol 30(5):717-723, 2003. e-Pub 2003. PMID: 14571419.
Guise TA, Chirgwin JM. Transforming growth factor beta in osteolytic breast cancer bone metastases. Clinical Orthop Relat Res (415 Suppl):S32-38, 2003. e-Pub 2003. PMID: 14600590.
Weissman BE, Dallas M, Guise TA, Leach RJ, Johnson-Pais, T. Chromosome 18 suppresses prostate cancer metastases. Urol Oncol 21(5):366-373, 2003. e-Pub 2003. PMID: 14670546.
Yin JJ, Mohammad KS, Käkönen SM, Harris S, Wu-Wong JR, Wessale J, Padley R, Garrett IR, Chirgwin JM, Guise TA. A causal role for endothelin-1 in the pathogenesis of osteoblastic metastases. Proc natl Acad Sci USA 100(19):1054-1059, 2003. e-Pub 2003. PMID: 12941866.
Kang Y, Siegel PM, Shu WP, Drobnjak M, Käkönen SM, Cordon-Cardo C, Guise TA, Massagué J. A multigenic program mediating breast cancer metastases to bone. Cancer Cell 3(6):537-549, 2003. e-Pub 2003. PMID: 12842083.
Kos C, Karaplis A, Goltzman D, Mohammad K, Guise, TA, Pollack M. The calcium-sensing receptor is required for normal calcium homeostatis independent of parathyroid hormone. J Clin Invest 111(7):1021-1028, 2003. e-Pub 2003. PMID: 12671051.
Lindemann RK, Braig M, Ballschmieter P, Guise TA, Nordheim A, Dittmer J. Protein kinase Ca regulates Ets1 transcriptional activity in invasive breast cancer cells. Int J Oncol 22(4):799-805, 2003. e-Pub 2003. PMID: 12632071.
Guise TA, Yin JJ, Mohammad K. Role of endothelin-1 in osteoblastic bone metastases. Cancer 97(3 (Suppl)):779-784, 2003. e-Pub 2003. PMID: 12548575.
Gallwitz WE, Guise, TA, Mundy, GR. Guanosine nucleotides inhibit the development of osteolytic bone disease due to metastatic breast cancer by their capacity to decrease PTHrP expression. J Clin Invest 110(10):1559-1572, 2002. e-Pub 2002. PMID: 12438453.
KaKonen, SM, Selander, KS, Chirgwin, JM, Yin, JJ, Burns, S, Rankin, WA, Grubbs, BG, Dallas, M, Cui, Y, Guise, TA. Transforming growth factorß stimulates parathyroid hormone-related protein and osteolytic metastases via Smad and mitogen-activated protein kinase signaling pathways. Biol Chem 277(27):24571-24578, 2002. e-Pub 2002. PMID: 11964407.
Guise, TA, Yin, JJ, Thomas, RJ, Dallas, M, Bui, Y, Gillespie, MT. Parathyroid hormone-related protein (PTHrP)-(1-139) isoform is efficiently secreted in vitro and enhances breast cancer metastasis to bone in vivo. Bone 30(5):670-676, 2002. e-Pub 2002. PMID: 11996903.
Wysolmerski, JJ, Dann, PR, Zelazny, E, Dunbar, MR, Insogna, KL, Guise, TA, Perkins, AS. Overexpression of parathyroid hormone-related protein causes hypercalcemia but not bone metastases in a murine model of mammary tumorigenesis. J Bone Miner Res 17(7):1167-1170, 2002. e-Pub 2002. PMID: 12096830.
Padalecki, SS, Guise, TA. Actions of bisphosphonates in animal models of breast cancer. Breast Cancer Res 4(1):35-41, 2001. e-Pub 2001. PMID: 11879558.
Chirgwin, JM, Guise, TA. Molecular mechanisms of tumor-bone interactions in osteolytic metastases. Crit Rev Eukaryot Gene Expr 10(2):159-178, 2000. e-Pub 2000. PMID: 11186331.
Vargas, GE, Uy, H, Bazan, C, Guise, TA, Bruder, JM. Hemiplegia after thryrotropin alfa in a hypothyroid patient with thyroid carcinoma metastatic to the brain. J Clin Endocrinol Metab 84(11):3867-3871, 1999. e-Pub 1999. PMID: 10566621.
Thomas, RJ, Guise, TA, Yin, JJ, Elliott, J, Horwood, NJ, Martin, TJ, Gillespie, MT. Breast cancer cells interact with osteoblasts to support osteoclast formation. Endocrinol 140(10):4451-4458, 1999. e-Pub 1999. PMID: 10499498.
Lemieux, PM, Guise, TA, Dallas, M, Oesterreich, S, Yin, JJ, Selander, K, Fuqua, SAW. Low cell motility induced by Hsp27 overexpression decreased osteolytic metastases formation by human breast cancer cells in vivo. J Bone Miner Res 14(9):1570-1575, 1999. e-Pub 1999. PMID: 10469286.
Boyce, BF, Yoneda, T, Guise, TA. Factors regulating the growth of metastatic cancer in bone. Endocr Relat Cancer 6(3):333-347, 1999. e-Pub 1999. PMID: 10516850.
Yin, JJ, Selander, KL, Chirgwin, JM, Dallas, M, Grubbs, BG, Wieser, R, Massaque, J, Mundy, GR, Guise, TA. TGFß signaling blockade inhibits parathyroid hormone-related protein secretion by breast cancer cells and bone metastases development. J Clin Invest 103(2):197-206, 1999. e-Pub 1999. PMID: 9916131.
Guise TA, Mundy GR. Cancer and Bone. Endocr Rev 19(1):18-54, 1998. e-Pub 1998. PMID: 9494779.
Mundy GR, Guise TA. Hypercalcemia of Malignancy. Am J Med 103(2):134-145, 1997. e-Pub 1997. PMID: 9274897.
Uy HL, Mundy GR, Boyce BF, Story BM, Dunstan CR, Yin JJ, Roodman GD, Guise TA. Tumor necrosis factor enhances parathyroid hormone-related protein (PTHrP)-induced hypercalcemia and bone resorption without inhibiting bone formation in vivo. Cancer Res 57(15):3194-3199, 1997. e-Pub 1997. PMID: 9242449.
Guise TA, Yin JJ, Taylor SD, Kumagai Y, Dallas M, Boyce BF, Yoneda T, Mundy GR. Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis. J Clin Invest 98(7):1544-1549, 1996. e-Pub 1996. PMID: 8833902.
Wysolmerski JJ, Vasavada R, Foley J, Weir EC, Burtis WJ, Kukreja SC, Guise TA, Broadus AE, Philbrick WM. Transactivation of the PTHrP gene in squamous carcinomas predicts the occurrence of hypercalcemia in athymic mice. Cancer Res 56(5):1043-1049, 1996. e-Pub 1996. PMID: 8640759.
Uy HL, Guise TA, De La Mata J, Taylor SD, Story BM, Dallas MR, Boyce BF, Mundy GR, Roodman GD. Effects of parathyroid hormone (PTH)-related protein and PTH on osteoclasts and osteoclast precursors in vivo. Endocrinol 136(8):3207-3212, 1995. e-Pub 1995. PMID: 7628353.
Guise TA, Mundy GR. Clinical review 69: Evaluation of hypocalcemia in children and adults. Clin Endocrinol Metab 80(5):1473-1478, 1995. e-Pub 1995. PMID: 7744987.
DeLaMata J, Uy HL, Guise TA, Story B, Boyce BF, Mundy GR, Roodman GD. Interleukin-6 enhances hypercalcemia and bone resorption mediated by PTH-rP in vivo. J Clin Invest 95(6):2846-2852, 1995. e-Pub 1995. PMID: 7769125.
Guise TA, Yoneda T, Yates AJP, Mundy GR. The combined effect of tumor-produced parathyroid hormone-related peptide and transforming growth factor a enhance hypercalcemia in vivo and bone resorption in vitro. J Clin Endocrinol Metab 77(1):40-45, 1993. e-Pub 1993. PMID: 8325957.
Garrett IR, Guise TA, Bonewald LF, Chizzonite R, Mundy GR. Evidence that interleukin-1 mediates its effects on bone resorption via the 80 kilodalton interleukin-1 receptor. Calcif Tissue Inter 52(6):438-441, 1993. e-Pub 1993. PMID: 8369991.
Guise TA, Garrett IR, Bonewald LF, Mundy GR. Interleukin-1 receptor antagonist inhibits hypercalcemia mediated by interleukin-1. J Bone Miner Res 8(5):583-587, 1993. e-Pub 1993. PMID: 8511985.
Guise TA, Chirgwin JM, Favarato G, Boyce BF, Mundy GR. Chinese hamster ovarian cells transfected with human parathyroid hormone-related protein cDNA cause hypercalcemia in nude mice. Lab Invest 67(4):477-485, 1992. e-Pub 1992. PMID: 1434529.

Invited Articles

Waning DL, Guise TA, Mohammad KS. A "Connexin" Responsible for the Fatal Attraction of Cancer to Bone. Cell Metab 29(1):6-8, 2019. e-Pub 2019. PMID: 30625309.
Heinrich D, Ø B, Guise TA, Suzuki H, Sartor O. Alkaline phosphatase in metastatic castration-resistant prostate cancer: reassessment of an older biomarker. Future Oncol 14(24):2543-2556, 2018. e-Pub 2018. PMID: 29925281.
Esposito M, Guise T, Kang Y. The Biology of Bone Metastasis. Cold Spring Harb Perspect Med 8(6):a031252, 2018. e-Pub 2018. PMID: 29101110.
Mohammad KS, Guise TA. Breaking Down Barriers to Chemoresistance: Role of Chemotherapy-Induced Osteoblastic Jagged1. Cancer Cell 32(6):717-718, 2017. e-Pub 2017. PMID: 29232546.
Regan JN, Trivedi T, Guise TA, Waning DL. The Role of TGFβ in Bone-Muscle Crosstalk. Curr Osteoporos Rep 15(12):18-23, 2017. e-Pub 2017. PMID: 28161871.
Mohammad KS, Guise TA. Hypercalcemia of Malignancy: A New Twist on an Old Problem. Oncol Pract 12(5):435-436, 2016. e-Pub 2016. PMID: 27170692.
Regan JN, Waning DL, Guise TA. Skeletal muscle Ca(2+) mishandling: Another effect of bone-to-muscle signaling. Semin Cell Dev Biol(49):24-29, 2016. e-Pub 2016. PMID: 26593325.
Waning DL, Guise TA. Cancer-associated muscle weakness: What's bone got to do with it?. Bonekey Rep(4):691, 2015. e-Pub 2015. PMID: 25992285.
Wright LE, Guise TA. The microenvironment matters: estrogen deficiency fuels cancer bone metastases. Clin Cancer Res 20(11):2817-2819, 2014. e-Pub 2014. PMID: 24803577.
Chiechi A, Waning DL, Stayrook KR, Buijs JT, Guise TA, Mohammad KS. Role of TGF- β in breast cancer bone metastases. Adv Biosci Biotechnol 4(10C):15-30, 2013. e-Pub 2013. PMID: 24558636.
Waning DL, Mohammad KS, Guise TA. Cancer-associated osteoclast differentiation takes a good look in the miR(NA)ror. Cancer Cell 24(4):407-409, 2013. e-Pub 2013. PMID: 24135278.
Guise, TA. Breast cancer bone metastases: it's all about the neighborhood. Cell 154(5):957-959, 2013. e-Pub 2013. PMID: 23993088.
Juarez P, Guise TA. Tgf-Beta pathway as a therapeutic target in bone metastases. Curr Pharm Des 16(11):1301-1312, 2010. e-Pub 2010. PMID: 20166877.
Guise, TA. Breaking down bone: new insight into site-specific mechanisms of breast cancer osteolysis mediated by metalloproteinases. Genes Dev 23(18):2117-2123, 2009. e-Pub 2009. PMID: 19759260.
Guise, TA. Antitumor effects of bisphosphonates: Promising preclinical evidence. Cancer Treat Rev 34(Suppl 1):S19-S24, 2008. e-Pub 2008. PMID: 18486348.
Mohammad KS, Chirgwin JM, Guise TA. Assessing new bone formation in neonatal calvarial organ cultures. Methods Mol Biol 455:37-50, 2008. e-Pub 2008. PMID: 18463809.
Brown SA, Clines GA, Guise TA. Local effects of malignancy on bone. Curr Opin Endocrinol Diabetes Obes 14(6):436-441, 2007. e-Pub 2007. PMID: 17982348.
Siclari VA, Guise TA, Chirgwin JM. Molecular interactions between breast cancer cells and the bone microenvironment drive skeletal metastases. Cancer Metastasis Rev 25(4):621-633, 2006. e-Pub 2006. PMID: 17165131.
Fournier P, Chirgwin JM, Guise TA. New insights into the role of T cells in the vicious cycle of bone metastases. Curr Opin Rheumatol 18(4):396-404, 2006. e-Pub 2006. PMID: 16763461.
Chirgwin JM, Guise TA. Does prostate-specific antigen contribute to bone metastases?. Clin Cancer Res 12(5):1395-1397, 2006. e-Pub 2006. PMID: 16533760.
Guise, TA. Thromboembolism to metastasis: The platelet-lysophosphatidic acid connection. IBMS BoneKEy, 2005. e-Pub 2005.
Guise TA, Kozlow WM, Heras-Herzig A, Padalecki SS, Yin JJ, Chirgwin JM. Molecular mechanisms of breast cancer metastases to bone. Clin Breast Cancer 5(Suppl 2):S46-53, 2005. e-Pub 2005. PMID: 15807924.
Aris RM, Guise TA. Cystic fibrosis and bone disease: are we missing a genetic link?. Eur Respir J 25(1):9-11, 2005. e-Pub 2005. PMID: 15640316.
Clines GA, Guise TA. Mechanisms and treatment for bone metastases. Clin Adv Hematol Oncol 2(5):295-301, 2004. e-Pub 2004. PMID: 16163196.
Guise TA, Mohammad KS. Endothelins in bone cancer metastases. Cancer Treat Res 118:197-212, 2004. e-Pub 2004. PMID: 15043194.
Heras-Herzig A, Guise TA. Effects of drug treatment for malignancy on skeletal health of cancer survivors. Clin Rev Bone Miner Metab 2(2):103-114, 2004. e-Pub 2004.
Chirgwin JM, Guise TA. Cancer metastases to bone. Science and Medicine 9:140-151, 2003. e-Pub 2003.
Guise TA, Mohammad KS, Käkönen SM, Chirgwin JM. Molecular mechanisms of bone metastases. American Society of Clinical Oncology Educational Book from 39th Annual Meeting:77-80, 2003. e-Pub 2003.
Guise, TA. How metastases home to bone: The attraction of chemokines. IBMS BoneKEy, 2002. e-Pub 2002.
Guise, TA. The vicious cycle of bone metastases. Journal of Musculoskeletal Neuron Interactions 2(6):570-572, 2002. e-Pub 2002. PMID: 15758398.
Guise, TA. Running with Grave’s disease. American Running Association Running & Fitness 20(3):7, 2002. e-Pub 2002.
Guise, TA. From chondrocytes to cancer: Fibroblast growth factor receptor 3 (FGFR3). Commentary in IBMS BoneKEy, 2001. e-Pub 2001.
Guise, TA. Molecular mechanisms of osteolytic metastases. Cancer 88((12 Suppl)):2892-2898, 2000. e-Pub 2000. PMID: 10898330.
Mundy GR, Guise TA. Hormonal control of calcium homeostasis. Clin Chem 45(8):1347-1352, 1999. e-Pub 1999. PMID: 10430817.
Boyce BF, Yoneda T, Guise TA. Molecular Basis of Bone Disease, Bone disease in malignancy. Advances in Organ Biology: Molecular and Cell Biology of Bone 5C(IV):709-738, 1998. e-Pub 1998.
Mundy GR, Guise TA. Role of parathyroid hormone-related protein in hypercalcemia of malignancy and osteolytic bone disease. Endocrine-Related Cancer 5:15-26, 1998. e-Pub 1998.
Guise, TA. Parathyroid hormone-related protein (PTHrP) and bone metastases. Cancer 80:1572-1580, 1997. e-Pub 1997. PMID: 9362424.
Guise, TA. Running “contact.”. Runner's World 32(5):17, 1997. e-Pub 1997.
Guise TA, Mundy GR. Physiological and pathological roles of parathyroid hormone-related peptide. Curr Opin Nephrol Hypertens 5(4):307-315, 1996. e-Pub 1996. PMID: 8823527.
Alsina M, Guise TA, Roodman GD. Cytokine regulation of bone cell differentiation. Vitam Horm 52:63-98, 1996. e-Pub 1996. PMID: 8909157.
Guise TA, Mundy GR. Breast cancer and bone. Curr Opin Endocrinol Diabetes Parathyroids and Bone and Mineral Metabolism(2):465-467, 1995. e-Pub 1995.
Guise, TA. Development of bone metastases and tumour osteolysis. Canadian J Diagnosis(Supplement):16-20, 1993. e-Pub 1993.

Review Articles

Hadji, P, Aapro, M, Al-Dagri, N, Alokail, M, Biver, E, Body, JJ, Brandi, ML, Brown, JE, Confavreux, C, Cortet, B, Drake, M, Ebeling, PR, Eriksen, EF, Fuleihan, GH, Guise, TA, Harvey, NC, Kurth, A, Langdahl, BL, Lems, W, Matijevic, R, McCloskey, EV, Nappi, R, Palacios, S, Pfeiler, G, Reginster, JY, Rizzoli, R, Santini, D, Tuzun, S, Poznak, CV, Villiers, TD, Zillikens, Mc, Coleman, R. Management of aromatase inhibitor-associated bone loss (AIBL) in women with hormone-sensitive breast cancer. Journal of Bone Oncology 53, 2025. e-Pub 2025. PMID: 40726588.
Nebgen DR, Domchek SM, Kotsopoulos J, de Hullu JA, Crosbie EJ, Paramanandam VS, Brood-van Zanten MMA, Norquist BM, Guise T, Rozenberg S, Kurian AW, Pederson HJ, Yuksel N, Michaelson-Cohen R, Bober SL, da Silva Filho AL, Johansen N, Guidozzi F, Evans DG, Menon U, Kingsberg SA, Powell CB, Grandi G, Marchetti C, Jacobson M, Brennan DJ, Hickey M. Care after premenopausal risk-reducing salpingo-oophorectomy in high-risk women: Scoping review and international consensus recommendations. BJOG 130(12):1437-1450, 2023. e-Pub 2023. PMID: 37132126.
Ballinger TJ, Thompson WR, Guise, TA. The bone-muscle connection in breast cancer: implications and therapeutic strategies to preserve musculoskeletal health. Breast Cancer Res 24(1):84, 2022. e-Pub 2022. PMID: 36419084.
Guise, TA, Wysolmerski JJ. Cancer-Associated Hypercalcemia. N Engl J Med 386(15):1443-1451, 2022. e-Pub 2022. PMID: 35417639.
Handley NR, Feng FY, Guise TA, D'Andrea D, Kelly WK, Gomella LG. Preserving Well-being in Patients With Advanced and Late Prostate Cancer. Urology 155:199-209, 2021. e-Pub 2020. PMID: 33373704.
Pagnotti GM, Thompson WR, Guise, TA, Rubin CT. Suppression of Cancer-associated bone loss through dynamic mechanical loading. Bone 150:115998, 2021. e-Pub 2021. PMID: 33971314.
Hussain A, Tripathi A, Pieczonka C, Cope D, McNatty A, Logothetis C, Guise T. Bone health effects of androgen-deprivation therapy and androgen receptor inhibitors in patients with nonmetastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis 24(2):290-300, 2021. e-Pub 2021. PMID: 33028943.
Javelaud D, Alexaki VI, Dennler S, Mohammad KS, Guise TA, Mauviel A. TGF-β/SMAD/GLI2 signaling axis in cancer progression and metastasis. Cancer Res 71(17):5606-10, 2011. e-Pub 2011. PMID: 21862631.
Mohammad KS, Fournier PG, Guise TA, Chirgwin JM. Agents targeting prostate cancer bone metastasis. Anticancer Agents Med Chem 9(10):1079-88, 2009. e-Pub 2009. PMID: 19719455.
Chirgwin JM, Guise TA. Skeletal metastases: decreasing tumor burden by targeting the bone microenvironment. J Cell Biochem 102(6):1333-42, 2007. e-Pub 2007. PMID: 17907152.

Abstracts

Pagnotti GM, Wilson R, Trivedi T, John SK, She Y, Murthy S, Wright LE, Suresh S, Rubin CT, Thompson KS, Mohammad KS, Guise TA. Low intensity vibration enhances the effects of zoledronic acid on bone mass and strength. American Society for Bone and Mineral Research Annual Meeting, Orlando, Fl, 2019, 2019. e-Pub 2019.
Trivedi T, Regan JA, Bahrami A, Rojas J, Reiken S, John S, Suresh S, Murthy M, She Y, Pagnotti G, Tersey SA, Cao X, Marks AR, Evans-Molina C, Mohammad KS, and Guise TA. Bone Derived TGF-β impairs glucose metabolism and insulin release by oxidation of RYR Ca+2 release channel in pancreatic β -cells in the setting of high bone turnover, aging and high fat diet. American Society for Bone and Mineral Research Annual Meeting, Orlando, Fl, 2019, 2019. e-Pub 2019.
Pagnotti GM, Pattyn RR, Wright LE, John SK, Murthy S, Trivedi T, She Y, Rubin CT, Thompson KS, Mohammad KS, Guise TA. Mechanical Signals Preserve Bone and Muscle While Suppressing Adiposity in a Murine Model of Complete Estrogen Deprivation. American Society for Bone and Mineral Research Meeting, Montreal, QC 2018, 2018. e-Pub 2018.
Trivedi T, Regan JN, Bahrami A, Rojas J, Reiken S, Pagnotti G, Tersey SA, Murthy S, John S, Xu Cao YS, Marks AR, Evans-Molina C, Mohammad KS, and Guise TA. Bone derived excess TGF-β impairs glucose metabolism and insulin release in mice with high bone turnover. Gordon research seminars and Gordon research conferences; Proctor Academy; Andover; NH; 2018, 2018. e-Pub 2018.
Yi X, Wright LE, Pagnotti GM, Uzer G, Rubin CT, Sankar U, Powell K, Wallace J, Mohammad KS, Guise TA, Thompson WR. Disruption of Nucleo-Cytoskeletal Connectivity Impairs Mechanical Competence of MDA-MB-231 Cells and Regulates Responses to Low Magnitude Mechanical Forces. American Society for Bone and Mineral Research Meeting, Montreal, QC 2018, 2018. e-Pub 2018.
Taipaleenmäki H, Saito H, Gasser A, Bolamperti S, Maeda M, Ring M, Shi Y, Matthies L, Schlüter H, Johnsen SA, Jähn K, Long CL, Haasper C, Gehrke T, Saini V, Pajevic PD, Bellido T, van Wijnen A, Mohammad KS, Guise TA, Hesse E. Tgif1 Controls Bone Remodeling and Anabolic Response to Parathyroid Hormone. American Society for Bone and Mineral Research Annual Meeting, Denver, CO, 2017, 2017. e-Pub 2017.
Trivedi T, Zheng Y, Fournier P, Dunstan C, Mohammad K, Zhou Z, Seibel M, Guise TA. The Vitamin D Receptor Promotes Human Breast Cancer Cell Growth via a Ligand Independent Cytoplasmic Function. ASBMR 35th Annual Meeting 2013, Baltimore, MD USA, 2013. e-Pub 2013.
Juarez P, Fournier P, Mohammad K, Mckenna RC, Lane D, Murthy S, Niewolna M, Robling A, Suva L, Chirgwin J, Guise TA. Beneficial Effects of Combined Therapy of Halofuginone and Zoledronic Acid on Breast Cancer Bone Metastases and Normal Bone Remodeling. ASBMR 35th Annual Meeting 2013, Baltimore, MD USA, 2013. e-Pub 2013.
Wright L, Joseph D, Harhash A, Waning D, John S, Mohammad K, Marks A, Guise TA. Effects of Sex Steroid Deprivation on Skeletal Muscle Function and Ryanodine Receptor (RyR1) Modulation. ASBMR 35th Annual Meeting 2013, Baltimore, MD USA, 2013. e-Pub 2013.
Juarez P, Mohammad K, Fournier P, Mckenna R, Lane D, Murthy M, Peng X, Suva L, Chirgwin J, Guise TA. Beneficial Effects of Combined Therapy Using Halofuginone and Zoledronic Acid on Breast Cancer Metastases to Bone and Normal Bone Remodeling. 12th International Conference on Cancer Induced Bone Diseases 2012, Lyon, France, 2012. e-Pub 2012.
Rhodes S, He Y, Wu X, Zhang P, Chen S, Jiang C, Yokota H, Indianapolis, USA, Yang X, Indiana, Peng X, Murthy S, Mohammad K, Guise TA, Yang FC. Hyperactive Transforming Growth Factor-beta1 Signaling Potentiates Fracture Non-union in Neurofibromatosis Type 1. ASBMR 34th Annual Meeting 2012, Minneapolis, MN USA, 2012. e-Pub 2012.
Buijs J, Matula K, Cheung H, van der Horst G, Mohammad K, Guise TA, Jonkers J, van der Pluijm G. Spontaneous Bone Metastasis in a Preclinical, Orthotopic Breast Cancer Model of Minimal Residual Disease (MRD): the Effect of TGF-β Signaling Inhibition. 12th International Conference on Cancer Induced Bone Diseases 2012, Lyon, France, 2012. e-Pub 2012.
Waning D, Mohammad K, Andersson D, John S, uarez-Camacho P, Center, Indiana University School of Reiken S, Marks A, Guise TA. Ryanodine receptor 1 Remodeling in Cancer Associated Muscle Dysfunction. ASBMR 34th Annual Meeting 2012, Minneapolis, MN USA, 2012. e-Pub 2012.
Stayrook K, Wei Y, Cerabona D, Fournier P, Edwards D, Niewolna M, Mohammad K, Kang Y, Guise TA. TGFß-Mediated Alteration in Sphingolipid Metabolism as a Potential Determinant in Osteolytic Bone Metastasis. ASBMR 34th Annual Meeting 2012, Minneapolis, MN USA, 2012. e-Pub 2012.
Mohammad K, John S, Peng X, Niewolna M, Murthy S, Laird AD, Aftab D, Guise TA. Cabozantinib Reduces Breast Cancer Bone Metastases and Improves Survival in a Mouse Model. 12th International Conference on Cancer Induced Bone Diseases 2012, Lyon, France, 2012. e-Pub 2012.
Mohammad KS, Waning WL, Andersson DC, John SK, Juarez-Camacho P, Reiken S, Marks AR, Guise TA. Remodeling of the ryanodine receptor 1 in cancer associated muscle dysfunction. Gordon Research Conference, Excitation-Contraction Coupling 2012, Les Diablerets Switzerland, 2012. e-Pub 2012.
Guise TA, Waning D, Mohammad K, Andersson D, Sutha John S, Juarez-Camacho P, Reiken S, Marks A. Cancer-associated Muscle Dysfunction: Role of Ryanodine Receptor 1 Remodeling. 12th International Conference on Cancer Induced Bone Diseases 2012, Lyon, France, 2012. e-Pub 2012.
Rhodes S, Menon K, He Y, Staser K, Chen S, Mohammad K, Guise TA, Yang FC. The Role of Osteoclasts in Neurofibromatosis Type 1 Pseudarthrosis. ASBMR 34th Annual Meeting 2012, Minneapolis, MN USA, 2012. e-Pub 2012.
Harhash A, Kozlow W, Niewolna M, McKenna C, Davis H, Mohammad K, Guise TA. Comparative Effects of Estrogen Depletion by Aromatase Inhibitors or Ovariectomy on Bone Mineral Density in Female Mice. 12th International Conference on Cancer Induced Bone Diseases 2012, Lyon, France, 2012. e-Pub 2012.
Li L, Li Z, Street C, Wang J, Rhodes S, Pan F, He Y, Mohammad K, Guise TA, Jin P, Xu M, Yang FC. Tet2 Plays an Important Role in Bone Remodeling by Regulating both Osteoblasto- and Osteoclasto-genesis Through the Maintenance of 5-Hydroxymethylcytosine in the Genome. ASBMR 34th Annual Meeting 2012, Minneapolis, MN USA, 2012. e-Pub 2012.
Hoggatt J, Mohammad KS, Chitteti BR, Singh P, Speth JM, Hu PR, Poteat B, Srour E, Guise T, Pelus LM. Bone Marrow Niche Attenuation by Non-Steroidal Anti-Inflammatory Drugs Mobilizes Hematopoietic Stem and Progenitor Cells by Differing Mechanisms. BLOOD 118(21):329-329, 2011. e-Pub 2011.
Juárez P, Mohammad K, McKenna R, Walton H, Peng X, Lane D, Niewolna M, Suva L, Chirgwin J, Guise TA. Combined therapy of Halofuginone and Zoledronic Acid inhibits Breast Bone Metastases. 11th International Conference on Cancer Induced Bone Diseases 2011, Chicago, IL USA, 2011. e-Pub 2011.
Buijs JT, Tedeschi L, Scheidler A, Peng X, John SK, Lane D, Murthy S, Chin-Sinex HJ, Mendonca MS, Bellido T, Bateman TA, Mohammad KS, Guise TA. Radiation-induced Bone Loss: Role of the Osteocyte. 11th International Conference on Cancer Induced Bone Diseases 2011, Chicago, IL USA, 2011. e-Pub 2011.
Wu X, Chen S, Rhodes SD, Li X, He Y, Yang X, Jiang L, Nalepa, G, Mohammad KS, Robling A, Conway S, Guise TA, Yang FC. Correction of Haploinsufficient Hematopoetic Microenvironment is Sufficient to Normalize the Pathological Fracture Repair in Genetically Engineered Murine Model of Neurofibromatosis Type. ASBMR 33th Annual Meeting 2011, San Diego, CA USA, 2011. e-Pub 2011.
Juárez P, Mohammad K, McKenna R, Walton H, Peng X, Lane D, Niewolna M, Suva L, Chirgwin J, Guise TA. Halofuginone Reduces Bone Metastases: TGF-β Dependent and Independent effects. ASBMR 33th Annual Meeting 2011, San Diego, CA USA, 2011. e-Pub 2011.
Rhodes SD, He Y, Wu X, Hong Chen L, Ping Z, Chen S, Jiang C, Yokota H, Peng X, Mohammad KS, Guise TA, Yang FC. Targeting the TFG- β/Smad Pathway in Neurofibromatosis Type 1 Skeletal Defects. ASBMR 33th Annual Meeting 2011, San Diego, CA USA, 2011. e-Pub 2011.
Mohammad KS, Waning WL, Andersson DC, John SK, Juarez-Camacho P, Reiken S, Marks AR, A Guise TA. Remodeling of the calcium release channel, ryanodine receptor 1, and muscle dysfunction in cancer cachexia-associated with bone metastases. 11th International Conference on Cancer Induced Bone Diseases 2011, Chicago, IL USA, 2011. e-Pub 2011.
Buijs JT, Tedeschi L, Peng X, Mendonca MS, Bellido T, Bateman TA, Mohammad KS, Guise TA. Radiation-induced Bone Loss: Role of the Osteocyte. ASBMR 33th Annual Meeting 2011, San Diego, CA USA, 2011. e-Pub 2011.
Wright L, Guise T, Mohammad K, Funk J. Curcuminoid Decrease Osteolytic Breast Cancer Bone Metastases Separate Effects on Tumor Cell Growth. ASBMR 33th Annual Meeting 2011, San Diego, CA USA, 2011. e-Pub 2011.
Buijs JT, Tedeschi L, Peng X, Mendonca MS, Bellido T, Bateman TA, Mohammad KS, Guise TA. Radiation-induced Bone Loss: Role of the Osteocyte. Fourth Fellows Forum on Metabolic Bone Diseases October 13-14, 2010, Toronto, Ontario, Canada, 2010. e-Pub 2010.
Mohammad KS, Dunn LA, Davis H, Peng X, Niewolna M, TA||B G, Chirgwin JM. Rapid-Onset Anabolic Actions on Bone of 2-Methoxyestradiol. ASBMR 32th Annual Meeting 2010, Toronto, Canada, 2010. e-Pub 2010.
Siclari VA, Mohammad KS, Guise TA, Chirgwin JM. Adrenomedullin overexpression increases osteolytic breast cancer metastases and growth in primary sites. ASBMR 31th Annual Meeting 2009, Denver, Colorado USA, 2009. e-Pub 2009.
Mohammad KS, Stebbins E, Niewolna M, McKenna CR, Peng X, Higgins L, Wong D, Guise TA. A p38 MAP Kinase inhibitor exacerbates osteolytic bone metastases due to breast and prostate cancer and has no effect on osteoblastic metastases. .ASBMR 31th Annual Meeting 2009, Denver, Colorado USA, 2009. e-Pub 2009.
Juárez P, Chirgwin J, Mohammad KS, McKenna R, Walton H, Niewolna M, Guise TA. Halofuginone decreases osteolytic bone metastases and TGF-β signaling. The IX International Meeting on Cancer Induced Bone Diseases 2009, Arlington, Virginia USA, 2009. e-Pub 2009.
Mohammad KS, Stebbins E, Niewolna N, McKenna CR, Peng X, Higgins L, Wong D, Guise TA. A p38 MAP Kinase inhibitor exacerbates osteolytic bone metastases due to breast and prostate cancer and has no effect on osteoblastic metastases. The IX International Meeting on Cancer Induced Bone Diseases 2009, Arlington, Virginia USA, 2009. e-Pub 2009.
Mohammad KS, Balooch G, Chen C, Stebbins E, Wong D, Derynck R, Suva L, Guise TA, Alliston T. Transforming Growth Factor β Receptor I Kinase Inhibitor Increases Bone Mass in Normal Mice. ASBMR 30th Annual Meeting 2008, Montreal, Canada, 2008. e-Pub 2008.
Mohammad KS, Stebbins E, Kingsley L, Fournier PGJ, Niewolna M, McKenna CR, Peng X, Higgins L, Wong D, Guise TA. Combined Transforming Growth Factor β Receptor I Kinase Inhibitor and Bisphosphonates are Additive to Reduce Breast Cancer Bone Metastases. ASBMR 30th Annual Meeting 2008, Montreal, Canada, 2008. e-Pub 2008.
Siclari VA, Mohammad KS, Guise TA, Chirgwin JM. Opposing Effects on Bone Metastases of Tumor Adrenomedullin Expression in Breast and Prostate Cancer. ASBMR 30th Annual Meeting 2008, Montreal, Canada, 2008. e-Pub 2008.
Mohammad KS, Kingsley L, La Vallee T, Guise TA, Chirgwin JM. Combined Transforming Growth Factor β Receptor I Kinase Inhibitor and Bisphosphonates are Additive to Reduce Breast Cancer Bone Metastases. ASBMR 30th Annual Meeting 2008, Montreal, Canada, 2008. e-Pub 2008.
Juárez P, Chirgwin J, Mohammad K, McKenna R, Walton H, Niewolna M, Javelaud D, Luciani F, Delmas V, Larue L, Mauviel A, Guise TA. Halofuginone Inhibits Melanoma Bone Metastases and TGF-beta Signaling. ASBMR 30th Annual Meeting 2008, Montreal, Canada, 2008. e-Pub 2008.
Crook MK, Mohammad K, Bartholin L, Carver A, Suva L, Chirgwin J, Wotton D, Guise TA. TGIF Regulation of Bone Mass: Impaired Osteoblast Differentiation. ASBMR 30th Annual Meeting 2008, Montreal, Canada, 2008. e-Pub 2008.
Fournier PGJ, Mohammad KS, McKenna RC, Peng X, Chirgwin JM, Guise TA. TGF-β Blockade Inhibits Osteolytic but not Osteoblastic Prostate Cancer Metastases. ASBMR 30th Annual Meeting 2008, Montreal, Canada, 2008. e-Pub 2008.
Mohammad KS, Stebbins EG, Kingsley LA, Fournier PGJ, Niewolna M, McKenna CR, Peng X, Higgins LS, Wong DH, Guise TA. Transforming growth factor β receptor I kinase inhibitor and bisphosphonates are additive to reduce breast cancer bone metastases. VII International Meeting on Cancer Induced Bone Diseases 2008, Edinburgh, Scotland, 2008. e-Pub 2008.
Mohammad KS, Kingsley L, La Vallee T, Guise TA, Chirgwin JM. 2-Methoxyestradiol Blocks Prostate Cancer Bone Metastases. ASBMR 30th Annual Meeting 2008, Montreal, Canada, 2008. e-Pub 2008.
Mohammad KS, Stebbins E, Kingsley L, Fournier PGJ, Niewolna M, McKenna CR, Peng X, Higgins L, Wong D, Guise TA. Combined Transforming Growth Factor β Receptor I Kinase Inhibitor and Bisphosphonates are Additive to Reduce Breast Cancer Bone Metastases. ASBMR 30th Annual Meeting 2008, Montreal, Canada, 2008. e-Pub 2008.
Mohammad KS, Kingsley L, La Vallee T, Guise TA, Chirgwin JM. 2-Methoxyestradiol Blocks Prostate Cancer Bone Metastases. ASBMR 30th Annual Meeting 2008, Montreal, Canada, 2008. e-Pub 2008.
Kingsley LA, Mohammad KS, Niewolna M, LaVallee T, Chirgwin JM, Guise TA. Inhibition of HIF1α Alone or Combined with TGFβ Blockade Prevents Breast Cancer Bone Metastases. ASBMR 30th Annual Meeting 2008, Montreal, Canada, 2008. e-Pub 2008.
Mohammad KS, Duong V, Kingsley LA, McKenna CR, Walton H, Suva LJ, Guise TA. Skeletal effects of 2-Methoxyestradiol in combination with other prostate cancer therapies. ASBMR 29th Annual Meeting 2007, Honolulu, HI, USA, 2007. e-Pub 2007.
Mohammad KS, Javelaud D, Stebbins EG, Niewolna M, McKenna CR, Peng X, Kingsley LA, Fournier PGJ, Higgins LS, Wong DH, Mauviel A, Guise TA. Transforming growth factor β receptor I kinase inhibitor reduces the development and progression of melanoma bone metastases. Skeletal Complications of Malignancy V 2007, Philadelphia, USA, 2007. e-Pub 2007.
Mohammad KS, Duong V, Kingsley LA, McKenna CR, Walton H, Suva LJ, Guise TA, Chirgwin JM. Skeletal effects of 2-methoxyestradiol in combination with other prostate cancer therapies. Skeletal Complications of Malignancy V 2007, Philadelphia, USA, 2007. e-Pub 2007.
Crook MK, Mohammad KS, Clines GA, Bartholin L, Melhuish T, McKenna CR, Niewolna M, Suva L, Carver A, Wotton D, Guise TA. Low bone mass in mice with null mutation in TG-interacting factor (TGIF): Impaired osteoblast function. ASBMR 29th Annual Meeting 2007, Honolulu, HI, USA, 2007. e-Pub 2007.
Mohammad KS, Javelaud D, Stebbins EG, Niewolna M, McKenna CR, Peng X, Kingsley LA, Fournier PGJ, Higgins LS, Wong DH, Mauviel A, Guise TA. Transforming growth factor β receptor I kinase inhibitor reduces the development and progression of melanoma bone metastases. ASBMR 29th Annual Meeting 2007, Honolulu, HI, USA, 2007. e-Pub 2007.
Siclari AV, Mohammad KS, Martinez A, Gineste C, Geysen HM, Guise TA, Chirgwin JM. Role of adrenomedullin in cancer, bone and metastasis. Skeletal Complications of Malignancy V 2007, Philadelphia, USA, 2007. e-Pub 2007.
Kakonen RS, Kakonen S, Mohammad KS, Rissanen JP, Halleen JM, Warri A, Nissinen L, Pihlavisto M, Chirgwin JM, Salmivirta M, Marjamaki A, Guise TA. Heparin-like polysacchrides markedly reduce osteolytic bone destruction and tumor growth in a mouse model of breast cancer bone metastasis. ASBMR 29th Annual Meeting 2007, Honolulu, HI, USA, 2007. e-Pub 2007.
Siclari AV, Mohammad KS, Martinez A, Gineste C, Geysen HM, Guise TA, Chirgwin JM. Development of small molecule adrenomedullin antagonist for treatment of bone metastases. ASBMR 29th Annual Meeting 2007, Honolulu, HI, USA, 2007. e-Pub 2007.
Mohammad KS, Javelaud D, Stebbins EG, Niewolna M, McKenna CR, Peng X, Kingsley LA, Fournier PGJ, Higgins LS, Wong DH, Mauviel A, Guise TA. Transforming growth factor β receptor I kinase inhibitor reduces the development and progression of melanoma bone metastases. Gordon Research Conference Bones & Teeth 2007, Biddeford, ME, USA, 2007. e-Pub 2007.
Mohammad KS, Stebbins EG, Niewolna M, McKenna CR, Peng XH, Balooch G, Chen C, Ritche R, Alliston T, Suva LJ, Higgins LS, Wong DH, Guise TA. Transforming growth factor β receptor I kinase inhibitor increases bone mass in normal mice. Skeletal Complications of Malignancy V 2007, Philadelphia, USA, 2007. e-Pub 2007.
Kozlow WM, Mohammad KS, McKenna CR, Walton H, Niewolna M, Guise TA. Ovariectomy decreases bone mass in young and old female athymic nude mice. ASBMR 29th Annual Meeting 2007, Honolulu, HI, USA, 2007. e-Pub 2007.
Mohammad KS, Duong V, Kingsley LA, McKenna CR, Walton H, Suva LJ, Guise TA, Chirgwin JM. Skeletal effects of 2-Methoxyestradiol in combination with other prostate cancer therapies. Gordon Research Conference Bone & Teeth 2007, Biddeford, ME, USA, 2007. e-Pub 2007.
Mohammad KS, Stebbins EG, Kingsley LA, Fournier PGJ, Niewolna M, McKenna CR, Peng X, Higgins LS, Wong DH, Guise TA. Combined transforming growth factor β receptor I kinase inhibitor and bisphosphonates are additive to reduce breast cancer bone metastases. Skeletal Complications of Malignancy V 2007, Philadelphia, USA, 2007. e-Pub 2007.
Mohammad KS, Javelaud D, McKenna CR, Niewolna M, Andre J, Delmas V, Larue L, Mauviel A, Guise TA. Stable overexpression of Smad7 in human melanoma inhibits bone metastasis in vivo. ASBMR 28th Annual Meeting 2006, Philadelphia, PA, USA, 2006. e-Pub 2006.
Guise TA, Stebbins EG, Mohammad KS, Niewolna M, McKenna CR, Mison AP, Li G, Schimmoller F, Murphy A Chakravarty S. Blocking TGF-beta signaling in breast cancer: Effects on bone and bone metastases. Sixth International Meeting on Cancer Induced Bone Diseases 2006, San Antonio, TX, USA, 2006. e-Pub 2006.
Mohammad KS, Stebbins EG, Niewolna M, McKenna CR, Walton H, Peng XH, Li G, Murphy A, Chakravarty S, Higgins LS, Wong DH, Guise TA. TGF-beta signaling blockade reduces osteolytic bone metastases and enhances bone mass. Sixth International Meeting on Cancer Induced Bone Diseases 2006, San Antonio, TX, USA, 2006. e-Pub 2006.
Siclari VA, Mohammad KS, Martinez A, Gineste C, Geysen HM, Guise TA, Chirgwin JM. Development of small molecule adrenomedullin antagonist for treatment of bone metastases. Sixth International Meeting on Cancer Induced Bone Diseases 2006, San Antonio, TX, USA, 2006. e-Pub 2006.
Mohammad KS, Bartholin L, Melhuish T, McKenna CR, Suva LJ, Carver A, Wotton D, Guise TA. Null mutation in TG-interacting factor (TGIF) causes abnormalities in skeletal development and low bone mass. ASBMR 28th Annual Meeting 2006, Philadelphia, PA, USA, 2006. e-Pub 2006.
Javelaud D, Mohammad KS, McKenna CR, Fournier P, Niewolna M, Andre J, Delmas V, Larue L, Guise TA, Mauviel A. Stable overexpression of Smad7 in human melanoma cells inhibits bone metastasis. Sixth International Meeting on Cancer Induced Bone Diseases 2006, San Antonio, TX, USA, 2006. e-Pub 2006.
Clines GA, Mohammad KS, Niewolna M, McKenna CR, Yanagisawa M, Clemens TL, Suva LJ, Chirgwin JM, Guise TA. Targeted deletion of the osteoblast endothelin A receptor alters bone formation in mice. Sixth International Meeting on Cancer Induced Bone Diseases 2006, San Antonio, TX, USA, 2006. e-Pub 2006.
Kozlow WM, Mohammad K, Niewolna M, McKenna CR, Walton H, Guise TA. The aromatase inhibitor letrozole has site-specific effects on the skeletons of female nude mice. Sixth International Meeting on Cancer Induced Bone Diseases 2006, San Antonio, TX, USA, 2006. e-Pub 2006.
Kozlow W, Mohammad KS, McKenna CR, Walton H, Niewolna M, Dilley JD, Suva LJ, Guise TA. Aromatase inhibition results in gain of bone mineral density in the spine and femur in female nude mice. ASBMR 28th Annual Meeting 2006, Philadelphia, PA, USA, 2006. e-Pub 2006.
Clines GA, Mohammad KS, Niewolna M, McKenna CR, Yanagisawa M, Clemens TL, Suva LJ, Chirgwin JM, Guise TA. Targeted deletion of the osteoblast endothelin A receptor alters bone formation in mice. ASBMR 28th Annual Meeting 2006, Philadelphia, PA, USA, 2006. e-Pub 2006.
Javelaud D, Mohammad KS, McKenna CR, Niewolna M, Andre J, Delmas V, Larue L, Guise TA, Mauviel A. Stable overexpression of Smad7 in human melanoma cells inhibits bone metastasis in vivo. ESDR 2006, Paris, France, 2006. e-Pub 2006.
Fournier PG, Mohammad KS, Chirgwin JM, Guise TA. TGF-β-regulated genes, IL-11, PTHrP and PMEPA1, are increased in bone metastases. ASBMR 28th Annual Meeting 2006, Philadelphia, PA, USA, 2006. e-Pub 2006.
Siclari VA, Clines GA, Mohammad KS, Guise TA, Chirgwin JM. Targets of the anabolic actions of Adrenomedullin on bone. Skeletal Complications of Malignancy IV 2005, NIH, USA, 2005. e-Pub 2005.
Mohammad KS, McKenna C, Mison A, Niewolna M, Vessella R, Corey E, Guise TA. Combined bisphosphonate and endothelin a receptor antagonist treatment more effectively reduces prostate cancer growth in bone than either alone. ASBMR 27th Annual Meeting 2005, Nashville, TN, USA, 2005. e-Pub 2005.
Clines GA, Mohammad KS, Chirgwin JM, Guise TA. Dickkopf homolog 1 (Dkk1) is a target of ET- 1 action in osteoblasts. Skeletal Complications of Malignancy IV 2005, NIH, USA, 2005. e-Pub 2005.
Mohammad K, McKenna R, Mason A, Chirgwin J, Guise TA. Effect of combined treatment with ETRA and ZA on osteoblastic bone metastases. Skeletal Complications of Malignancy IV 2005, NIH, USA, 2005. e-Pub 2005.
Kozlow W, Mohammad K, McKenna R, Niewolna M, Suva L, Rosen C, Guise TA. Aromatase inhibition causes lower bone density than ovariectomy in mice, an effect prevented by bisphosphonates. ASBMR 27th Annual Meeting 2005, Nashville, TN, USA, 2005. e-Pub 2005.
Stebbins EG, Mohammad KS, Niewolna M, McKenna CR, Mison AP, Schimmoller F, Murphy A, Chakravarty S, Dugar S, Higgins LS, Wong DH, Guise TA. SD-208, a small molecule inhibitor of transforming growth factor β receptor I kinase reduces breast cancer metastases to bone and improves survival in a mouse model. ASBMR 27th Annual Meeting 2005, Nashville, TN, USA, 2005. e-Pub 2005.
Mohammad KS, McKenna C, Mison A, Niewolna M, Vessella R, Corey E, Guise TA. Combined endothelin A receptor antagonist and bisphosphonate treatment more effectively reduces prostate cancer growth in bone than either alone. Ninth International Conference on Endothelin (ET-9) 2005, Park City, UT, USA, 2005. e-Pub 2005.
Clines GA, Mohammad KS, Wessner LL, Chirgwin JM, Guise TA. Endothelin-1 stimulates bone formation by regulating osteoblast secretion of the paracrine regulators IL-6, Cyr61, CTGF and Dkk1. ASBMR 27th Annual Meeting 2005, Nashville, TN, USA, 2005. e-Pub 2005.
Kozlow W, Mohammad K, McKenna R, Niewolna M, Guise TA. Aromatase inhibition results in lower bone density than ovariectomy in mice, an effect prevented by bisphosphonates. Skeletal Complications of Malignancy IV 2005, NIH, USA, 2005. e-Pub 2005.
Clines GA, Mohammad KS, Chirgwin JM, Guise TA. Endothelin-1 stimulates osteoblast production of interleukin-6, connective tissue growth factor (CTGF) and Cyr61. Ninth International Conference on Endothelin (ET-9) 2005, Park City, UT, USA, 2005. e-Pub 2005.
Clines GA, Mohammad KS, Chirgwin JM, Guise TA. Endothelin-1 stimulates pathologic bone formation through repression of the negative Wnt regulator Dickkopf Homolog 1 (DKK1). Ninth International Conference on Endothelin (ET-9) 2005, Park City, UT, USA, 2005. e-Pub 2005.
Clines GA, Mohammad KS, Chirgwin JM, Guise TA. Regulation of Dickkopf homolog (DKK1) expression by endothelin-1 (ET-1): Implications in the pathogenesis of osteoblastic metastases. JBMR 19 (S1) S133, 2004, 2004. e-Pub 2004.
Mohammad KS, Wang Z, Martinez A, Corey E, Vessella RL, Guise TA, Chirgwin JM. Adrenomedullin is made by prostate cancers and increases both osteolytic and osteoblastic bone metastases. JBMR 19(S1):S25, 2004, 2004. e-Pub 2004.
Mohammad KS, Guise TA, Chirgwin JM. PTHrP stimulates new bone formation by molecular mimicry of endothelin-1. JBMR 18(2):S26, Sep 2003, 2003. e-Pub 2003.
Mohammad KS, Guise TA. Endothelin A receptor blockade alters bone remodeling: Gender- specific and sex steroid-dependent changes. JBMR 18(2):S310, Sep 2003, 2003. e-Pub 2003.
Käkönen SM, Mohammad KS, Käkönen RS, Marjamäki A, Wärri A, Salmivirta M, TA <. A low- molecular-weight heparin markedly reduced osteolytic bone destruction in a mouse model of breast cancer bone metastases. JBMR 18(2):S63, Sep 2003, 2003. e-Pub 2003.
Mohammad KS, Guise TA, Chirgwin JM. PTHrP fragments stimulate new bone formation by binding to the endothelin A receptor. The VI International Conference on Cancer Induced Bone Diseases, 2003, 2003. e-Pub 2003.
Mohammad KS, Yin JJ, Grubbs B, Cui Y, Padley R, Guise TA. Gender-specific role of endothelin-1 in pathological bone remodeling. Twenty Third Annual American Cancer Society, Virginia Division 2003, Charlottesville, VA, USA, 2003. e-Pub 2003.
Chirgwin JM, Martinez A, Wang Z, Mohammad KS, Guise TA. Tumor Adrenomedullin increases bone metastases in lung and prostate cancers. Sixth International Conference on Cancer Induced Bone Diseases 2003, Washington, DC, USA, 2003. e-Pub 2003.
Mohammad KS, Guise TA. Endothelin A receptor blockade alters bone remodeling by gender- specific and sex steroid-dependent mechanisms. Eighth International Conference on Endothelin (ET-8) 2003, Japan, 2003. e-Pub 2003.
Guise TA, Mohammad KS, Chirgwin JM. Breast cancers secrete ndothelin-1 and cause osteoblastic bone metastases by activation of the endothelin A receptor. Eighth International Conference on Endothelin (ET-8)2003, Japan, 2003. e-Pub 2003.
Chirgwin JM, Mohammad KS, Guise TA. Parathyroid hormone-related protein [PTHrP] fragments are potent agonists of the endothelin A receptor. Eighth International Conference on Endothelin (ET8) 2003, Japan, 2003. e-Pub 2003.
Mohammad KS, Yin JJ, Grubbs B, Cui Y, Padley R, Guise TA. Gender-specific role of endothelin- 1 in pathological bone remodeling. Third North American Symposium on Skeletal Complications of Malignancies. National Institute of Health, 2002, Bethesda, MD, USA, 2002. e-Pub 2002.
Mohammad KS, Guise TA, Chirgwin JM. PSA converts parathyroid hormone-related protein (PTHrP) from an osteolytic to an osteoblastic factor: Role in prostate cancer bone metastases. Twenty Third Annual American Cancer Society, Virginia Division 2003, Charlottesville, VA, USA, 2002. e-Pub 2002.
Mohammad KS, Yin JJ, Cui Y, Grubbs B, Guise TA. Effect of endothelin A (ETA) receptor blockade on bone remodeling. Eleventh Annual Symposium on Cancer Research 2001, San Antonio TX, USA, 2001. e-Pub 2001.
Mohammad KS, Yin JJ, Grubbs B, Cui Y, Padley R, Guise TA. Endothelin-1 (ET-1) mediates pathological but not normal bone remodeling. ET-7 Seventh International Conference on Endothelin 2001, University of Edinburgh, Scotland, UK, 2001. e-Pub 2001.
Mohammad KS, Yin JJ, Cui Y, Grubbs B, TA||B G. Effect of endothelin A (ETA) receptor blockade on bone remodeling. UTHSCSA Medicine Research Day 2001, San Antonio TX, USA, 2001. e-Pub 2001.

Book Chapters

Loots, GG, Guise, TA. Mechanisms Underlying Osteolytic and Osteoblastic Bone Metastases, 17-35, 2024.
Joseph D, Guise TA. Approach to the patient with hypercalcemia. In: Oxford Textbook of Clinical Nephrology. Fourth. Oxford Prss, 2015.
Clines GA, Guise TA. Hypercalcemia of malignancy. In: Medical Care of Cancer Patients. Peoples Medical Publishing House, 188-193, 2009.
Heras-Herzig A, Kozlow W, Brown S, Guise TA. Osteoporosis associated with cancer and cancer treatment. In: Osteoporosis. Third. Academic Press, 1337-1374, 2008.
Bartholin, L, Guise, TA. TGF in breast cancer osteolysis. In: TGF in Health and Disease, 2007.
Clines GA, Guise TA. Mechanisms of bone destruction and bone formation by metastatic tumors. In: Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. Sixth. American Society for Bone and Mineral Research, 2006.
Heras-Herzig A, Guise TA. Disorders of calcium metabolism. In: Therapy of Renal Diseases and Related Disorders. Fourth. Kluwer Academic Publishers, 2006.
Clines GA, Chirgwin JM, Guise TA. Skeletal complications of malignancy: Central role for the osteoclast. In: Topics in Bone Biology. Springer-Verlag, 151-174, 2005.
Mohammad KS, Guise TA. Osteoblastic bone metastases. In: Bone Metastases. First. Chung, 2004.
Guise TA, Chirgwin JM. Biology of bone metastases. In: Diseases of the Breast. Third. Lippman, Morrow and Osborne, 1285-1296, 2004.
Clines GA, Guise TA. Hypercalcaemia in hematologic malignancies and in solid tumors associated with extensive localized bone destruction. In: Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. Fifth. American Society for Bone and Mineral Research, 251-253, 2003.
Guise, TA. Therapy affecting bone resorption and deposition. In: Management of Metastatic Disease to the Musculoskeletal System. Quality Medical Publishing, 107-138, 2002.
Mundy GR, Yoneda T, Guise TA, Oyajobi B. Local factors in skeletal malignancy. In: Principles of Bone Biology. Second. Academic Press, 1093-1104, 2002.
Bruder JA, Guise TA, Mundy GR. Disorders of calcium metabolism. In: Endocrinology and Metabolism. Fourth. McGraw Hill Book Company, 1079-1159, 2001.
Mundy GR, Guise TA. Pathophysiology of bone metastasis. In: Cancer and the Skeleton. Martin Dunitz Ltd, 43-64, 2000.
Guise TA, Mundy GR. Disorders of calcium homeostasis. In: The Kidney: Physiology and Pathophysiology. Third. Lippincott, Williams & wilkins, 1811-1839, 2000.
Mundy GR, Guise TA. Biology of bone metastases. In: Diseases of the Breast. Second. Lippman, Morrow and Osborne, 911-920, 1999.
Mundy GR, Yoneda T, Guise TA. Hypercalcaemia in hematologic malignancies and in solid tumors associated with extensive localized bone destruction. In: Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. Fourth. Lippincott Williams & Wilkins, 208-212, 1999.
Guise TA, Mundy GR. Disorders of calcium metabolism. In: Therapy of Renal Diseases and Related Disorders. 3rd. Kluwer Academic Publishers, 85-114, 1997.

Letters to the Editor

Kiel, DP, Guise, TA, Styner, M, Rubin, J. Concerns about the paper, “Benefits of targeted vibration for bone strength and bone density in postmenopausal women with osteopenia. JBMR Plus 9, 2025.

Patents

Yoneda T, Mundy GR, Guise TA. Method to ameliorate osteolysis and metastasis. Patent Number: 5,993,817.

Less

CV information above last modified December 02, 2025

Theresa A. Guise, M.D., FASBMR

About Dr. Theresa A. Guise

In the News

What causes chemobrain? New insights

Present Title & Affiliation

Dual/Joint/Adjunct Appointment

Education & Training

Degree-Granting Education

Postgraduate Training

Licenses & Certifications

Experience & Service

Faculty Academic Appointments

Administrative Appointments/Responsibilities

Other Professional Positions

Extramural Institutional Committee Activities

Editorial Activities

Professional Memberships

Selected Presentations & Talks

Local Presentations

Regional Presentations

National Presentations

International Presentations

Formal Peers

Grant & Contract Support

Selected Publications

Peer-Reviewed Articles

Invited Articles

Review Articles

Abstracts

Book Chapters

Letters to the Editor

Patents

Patient Reviews

Related Links

Care Centers and Clinics

Departments and Divisions

Labs

Help #EndCancer

Theresa A. Guise, M.D., FASBMR

About Dr. Theresa A. Guise

In the News

What causes chemobrain? New insights

Present Title & Affiliation

Dual/Joint/Adjunct Appointment

Education & Training

Degree-Granting Education

Postgraduate Training

Licenses & Certifications

Experience & Service

Faculty Academic Appointments

Administrative Appointments/Responsibilities

Other Professional Positions

Extramural Institutional Committee Activities

Editorial Activities

Professional Memberships

Selected Presentations & Talks

Local Presentations

Regional Presentations

National Presentations

International Presentations

Formal Peers

Grant & Contract Support

Selected Publications

Peer-Reviewed Articles

Invited Articles

Review Articles

Abstracts

Book Chapters

Letters to the Editor

Patents

Patient Reviews

Request an Appointment

Related Links

Care Centers and Clinics

Departments and Divisions

Labs

Clinical Trials

Help #EndCancer

Give Now

Donate Blood

Shop MD Anderson